

CURRICULUM VITAE

- 1. Name:** **JUDITH ANN JOHNSON, PH.D.**

- 2. Office Address:** University of Florida
PO Box 100009
Room 274
Emerging Pathogens Institute
Gainesville, FL 32610-0009
Telephone: (352) 273-9428
Fax: (352) 273-9430

- 3. E-Mail Address:** jajohnson@pathology.ufl.edu

- 4. Current Titles and Affiliations:**

2007 - present	<u>Research Professor</u> Department of Pathology, Immunology, and Laboratory Medicine College of Medicine, and
2007 - present	<u>Director</u> Core Laboratories; Emerging Pathogens Institute, University of Florida; Gainesville, FL, USA
2011 - present	<u>Joint Professor:</u> Department of Medicine, Division of Mycobacteriology, College of Medicine, University of Florida; Gainesville, FL, USA
2008 - present	<u>Member Graduate Faculty,</u> University of Florida Graduate School; Gainesville, FL

- 5. Previous Academic and Professional Appointments:**

1999 - 2007	<u>Associate Professor</u> Department of Pathology, University of Maryland School of Medicine, Baltimore, MD
1998 - 2007	<u>Chief,</u> Microbiology and Molecular Diagnostics, Veterans Affairs Maryland Health Care System, Baltimore, MD
1999 - 2007	<u>Regular Member,</u> Graduate Faculty, University of Maryland Graduate School, Baltimore, MD
1998 - 2001	<u>Special Member,</u> Graduate Faculty, University of Maryland Graduate School, College Park, MD
2000 - 2007	<u>Associate Professor, secondary appointment,</u> Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD
1993 - 2000	<u>Assistant Professor, secondary appointment,</u> Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
1999 - 2000	<u>Associate Professor, secondary appointment,</u> Department of Medicine, Division of Hospital Epidemiology, University of Maryland School of Medicine, Baltimore, Maryland.
1994 - 1999	<u>Associate Member,</u>

1993 - 1999 Graduate Faculty,
University of Maryland Graduate School, Baltimore, Maryland.
Assistant Professor
Department of Pathology, University of Maryland School of
Medicine,
Baltimore, Maryland.

1993 - 1998 Scientific Director,
Molecular Diagnostic Laboratory, Veterans Affairs Maryland Health
Care System, Baltimore, Maryland.

1982-1990 Graduate Teaching Assistant,
Department of Microbiology, University of Maryland, College Park

1977-1982 Medical Technologist, Microbiology Section,
Prince George's General Hospital & Medical Center, Cheverly, MD

6. Education

1977 B.S., University of Maryland at College Park (Microbiology)
1990 Ph.D., University of Maryland at College Park (Microbiology)

7. Postdoctoral Training:

1990-1993 Center for Vaccine Development, University of Maryland School of
Medicine

8. Certifications

1978 - present M(ASCP)
1978 - present RM(AAM)

9. Committee Memberships

a. National and International

1975 - present Member of the American Society for Microbiology
1983 Member of the American Academy of Microbiology, National
Registry of Microbiologists Examination Development Committee

1986 - 2003 Member of the American Association for the Advancement of Science

1995 - 2005 Member of the American Association of University Women

1996 - 2002 External Reviewer, USDA - Insuring Food Safety grant program

2004 Reviewer Virulence Factor Activity Relationships (VFAR)
with Specific Emphasis on *Aeromonas* species (spp.). Ashok K.
Chopra, EPA Workshop on Virulence Factor-Activity Relationships

2005 External Reviewer, Grant for Wisconsin Water Resources
Institute (WRI)

2005 External Reviewer, NSF OISE- International Fellows Program

b. Local

1988 Graduate Student Member, Faculty Search Committee,
Department of Microbiology, UMCP

1993 External Reviewer, Maryland Sea Grant pre-proposals

1993 - 1998 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Research and Development Committee

1993 - 2007 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Pathology and Laboratory Medicine Service, Total
Quality Improvement Committee

1994 Member, Veterans Affairs Maryland Health Care System,

1994 - 2007 Baltimore, Research Budget Committee
American Society for Microbiology, Maryland Branch
1995 - 1998 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Research Resources Committee
1995, 1996 American Society for Microbiology, Maryland
Branch Judge, Student Science Fair
1996, 1997, 1999 Judge - UMAB/UMBC Graduate Student Research Day
1997-1998 Alternate Councilor, Maryland Branch, American Society
for Microbiology
Baltimore, Research Seminar Committee
1998- 1999 Councilor, Maryland Branch, American Society for Microbiology
1998 - 1999 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Dream Team
1998 - 2004 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Core Equipment Committee
1998 Member, Productivity Committee, Pathology Department,
University of Maryland, Baltimore
1999 - 2007 Member, Pathology Department Mentoring Program, UMB
1999 - 2005 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Infection Control Subcommittee
1999 - 2005 Member, Veterans Affairs Maryland Health Care System,
Executive Infection Control Committee
1999- 2000 Pathology Department Planning Program Leader -
Infectious Diseases, University of Maryland, Baltimore
1999 - 2007 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Animal Use Committee
1999- 2000 Vice President, Maryland Branch, American Society for Microbiology
2000- 2001 President Elect, Maryland Branch, American Society for
Microbiology
2000 - 2001 Alternate, University of Maryland School of Medicine
Council, University of Maryland, Baltimore
2000 - 2005 Pathology Department Graduate Admissions Committee,
University of Maryland, Baltimore
2001- 2005 Assistant Secretary/Treasurer - Baltimore Research and
Education Foundation
2001 - 2002 President, Maryland Branch, American Society for Microbiology
2002 - 2003 Past President, Maryland Branch, American Society for Microbiology
2001 - 2007 Member, Veterans Affairs Maryland Health Care System,
Baltimore, Human Studies Subcommittee
2003 CAP inspection team for St. Mary's Hospital
2005 - 2007 Member, Veterans Affairs Maryland Health Care System,
Acute Care Infection Control Subcommittee
2005 - 2007 Member, Pathology Research Advisory Committee,
Pathology Department, University of Maryland, Baltimore
2005 CAP inspection team for Mercy Hospital
2005 - 2007 Secretary/Treasurer - Baltimore Research and Education Foundation
2006 CAP inspection team for St. Agnes Hospital
2006 HFMEA (Healthcare Failure Mode and Effect Analysis)
Team for Isolation, Veterans Affairs Maryland Health Care System
2006 - 2007 Pandemic Influenza Work Group, Veterans Affairs Maryland
Care System Health
2006 - 2007 VHAPTH MRSA Prevention Initiative – Getting to Zero, Laboratory
Representative, Veterans Affairs Maryland Health Care System
2007 - 2008 DRL Test Development Committee, Department of Pathology, COM
2007 - 2010 Building Committee, Emerging Pathogens Institute

2008	Chair, Search Committee for faculty candidate, Emerging Pathogens Institute
2008	CAP inspection team for Lab Corp Laboratory, Atlanta, Georgia
2008	Member, Search Committee for faculty candidate, College of Pharmacy and Emerging Pathogens Institute
2008	Member, Search Committee for faculty candidate, IFAS and Emerging Pathogens Institute
2008 - 2011	Mentoring Committee for Dr. Bin Gao, IFAS, Department of Agricultural and Biological Engineering
2008 - 2009	Member, Resistant Pathogen Taskforce, Shands Health Care
2008, 2009	Extramural Consultant for Merit Review proposal, Malcom Randall VA Medical Center
2008, 2009	Member, Search Committee for faculty candidate, Emerging Pathogens Institute
2008 – present	Member, EPI seminar Committee
2009	Member, Search Committee for building manager, Emerging Pathogens Institute
2009 - 2011	Chair, Equipment Committee, Emerging Pathogens Institute
2010 - 2011	Member, Search Committee for faculty candidate, Emerging Pathogens Institute and Plant Pathology
2010 - 2012	Member, Seminar Committee, Emerging Pathogens Institute
2012	Member, Search Committee for faculty candidate, Emerging Pathogens Institute
2012	Judge, Poster session South Eastern Branch ASM meeting, Athens GA

10. Manuscript Reviewer:

Vibrio cholerae and Cholera: Molecular to Global Perspectives.

1994. ASM, Washington DC	1993
Clinical Infectious Diseases	1996 - 2005
Infection and Immunity	1997 - 2004
Clinical and Diagnostic Laboratory Immunology	1998
Journal of Clinical Microbiology	2003 - present
Emerging Infectious Diseases	2004 - present
Clinical Microbiology Reviews	2006
Antimicrobial Agents and Chemotherapy	2006
Applied and Environmental Microbiology	2006 - present

11. Honors and Awards:

1984	Isabel R. MacDonald Award to an Outstanding Graduate Student, Department of Microbiology, University of Maryland
1988	Andrew J. Moyer Award to an Outstanding Graduate Student, Department of Microbiology, University of Maryland
1994	Scientific and Technological Achievement Rewards (STAR) Award, United States Environmental Protection Agency, Risk Reduction Engineering Laboratory

12. Research Focus:

Microbial pathogenesis - Ongoing projects: the role of surface polysaccharides in pathogenesis and immunity of *Vibrio* spp.; virulence of community associated *Staphylococcus aureus* in lung infections, virulence factors in Mycobacteria and Acinetobacter.

Infection Control - Development of self-sterilizing devices; extended spectrum beta-lactamase resistance in Gram-negative bacteria.

Molecular epidemiology/Phylogeography - Ongoing projects: Phylogeography of cholera; molecular typing of methicillin resistant *Staphylococcus aureus* (MRSA) and other organisms; and diarrheal infections in the developing world.

Microbial ecology - Ongoing projects: Environmental reservoirs of nontuberculous mycobacteria and vibrios: MRSA in Cepheids.

Microbial genetics - Ongoing projects: evolution of *Vibrio* spp., *Bacillus*, and *Staphylococcus aureus* genomes and pathogenicity islands

13. Patents:

5653986 Morris, J.G., Jr., Johnson, J.A., and Bush, C.A. "*Vibrio cholerae* Bengal serogroup-O139 capsular polysaccharide, protein conjugates thereof" (U.S. Patent, awarded 8/5/97)

60/761,225 Panigrahi P, Johnson J, Gewolb IH, Parida SN, Misra PR, Mohapatra SS, Pradhan L, Satpathy R "*Fructo-oligosaccharide and Lactobacillus Combination and Uses Thereof*" (pending)

14. Grant Support:

a. Active Grant Support

Principle Investigator

Other

- NIH R01 AI097405 (Morris) 12/01/11 - 11/30/15 \$594,565
Cholera transmission in Gressier region, Haiti
Role – Co- investigator

- Commercialization Fund Proposal-UF (Roy) UF#-14898 10/01/13 – 3/31/14 \$30,000
Pool Cleaning Application of Water Purifier
Role – Co- investigator

Role – Co-Investigator- DHS (Morris) 06/01/10 - 5/31/15 \$70,000
National Center of Excellence for Food Security
Role – Co-I

b. Pending Grants

Principle Investigator

- NIH 4/01/14 – 3/31/19 \$2,349,428
Bacterial genetic response to gas plasma injury

c. Previous Support

Principle Investigator

1/1/94 - 12/30/95 Colonization and Biofilm Formation - Rugose *Vibrio cholerae* Model. Department of Veterans Affairs RAGS
Total direct costs: \$100,000
4/1/96 - 3/31/99 Genetics of the Rugose Survival Form of *Vibrio cholerae*.
Department of Veterans Affairs Merit Review
Total direct costs: \$212,000

- 5/1/94 - 4/30/99
Current year direct costs: \$65,800
Continuation of VA RAGS project
Pathogenesis of *Vibrio cholerae* O139 Synom. Bengal
NIH-R29, AI35729
Total direct costs: \$350,000, total costs: \$440,661
- 3/1/98 – 2/28/00
Current year direct costs: \$69,408
Quinupristin/Dalfopristin Resistant *Enterococci* in Poultry
Pfizer Inc.
Total direct costs: \$105,780
Principal Investigator: Richard Schwalbe (deceased)
Change of P.I. to Judith A. Johnson 11/98
- 6/1/99 - 12/31/00
Activity of Tetracycline Derivatives Against Gram-
Positive Bacteria
Paratek, Inc.
Total direct costs \$67,076
- 6/1/03 - 6/30/04
Evaluation of the PHOENIX™ Automated Microbiology
System.
BD Biosciences
Total direct costs: \$63,900
- 6/1/02 - 12/31/02
Clinical Impact of Blood Culture Collection Methods
BD Biosciences
Total direct costs: \$48,000
- 10/1/01 - 9/30/04
Antibiotics and Resistant *Enterococci*.
Department of Veterans Affairs Merit Review
Total direct costs: \$550,000
- Other**
- 7/1/93 - 6/30/95
Impact of Rugose Survival Form of *Vibrio cholerae*
O1 on Transmission of Cholera.
Thrasher Research Foundation
Principal Investigator: J. Glenn Morris, Jr., M.D.
Co-principal: Judith A. Johnson, Ph.D.
Total direct costs: \$85,354
- 8/1/95 - 7/30/96
Molecular Epidemiology and Identification of Common
Surface Antigens in *Enterococci*, MIPS, Phase II
Principal Investigator: Richard Schwalbe
Co-investigator: Judith A. Johnson, Ph.D.
Total direct costs \$84,000, total costs: \$105,000
- 9/1/96 - 8/31/97
Preliminary Exploration of Molecular Methods for the
Specific Detection and Differentiation of the *Bdellovibrios*.
National Science Foundation
Principal Investigator: Henry N. Williams
Co-investigator: Judith A. Johnson
Total direct costs \$51,720, total \$74,994
- 11/1/97 - 10/31/98
Assessment of the predictive value of water temperature and
other environmental parameters on occurrence of cholera
Thrasher Research Foundation
Principal Investigator: J. Glenn Morris, Jr., M.D.
Co-Principal Investigator: Judith A. Johnson,
Total Direct costs, \$66,940, Total Costs \$69,961
- 9/1/96 – 12/31/98
A Proposal for an Emerging Infections Program in
Maryland, Centers for Disease Control and Prevention
Principal Investigators: Diane Dwyer, Lee H. Harrison, J.
Glenn Morris, Jr.
Co-investigator: Judith A. Johnson, Ph.D.

1/1/98 – 9/30/98
Total direct costs \$1,497,846, total costs: \$1,835,841
First year direct costs: \$475,850 (UMAB \$72,201)
NSF OCE-97310055
Assesment of Diversity Among Bdellovibrios
Total direct costs: \$60,000
Principal Investigator: Henry N. Williams
Consultant: Judith A. Johnson

10/1/98 – 9/30/99
Dose-response to Vibrio species
FDA
Principal Investigator: J. Glenn Morris, Jr., M.D.
Co-Investigator: Judith A. Johnson, ,
Total Direct costs, \$721,637; Total Costs \$941 ,967

10/1/97 - 9/30/00
Emergence of new pathogens: Role of horizontal gene transfer in Vibrio. Department of Veterans Affairs, VA/DOD
Principal investigator: J. Glenn Morris, Jr.
Co-investigator: Judith Johnson
Total direct costs: \$300,000
Current year direct costs \$99,956

2/1/00 – 1/31/01
Risk Assesment of Use of Quinupristin/Dalfopristin in Animals/Animal Feed
Pfizer Inc.
Total direct costs: \$135,000
Principal Investigator: J. Glenn Morris, Jr.
Co-investigator: Judith Johnson

7/1/99 – 6/30/03
Analysis of the *Vibrio cholerae* Pathogenicity Island
NIH RO1
Total direct costs: \$1,039,798, Total costs: \$1,537,553
First year direct costs: \$196,982
Principal Investigator: David Karaolis
Co-investigator: Judith A. Johnson,

6/1/00 - 5/31/01
Evaluation of the PHOENIX™ Automated Microbiology System.
BD Biosciences
Principal Investigator: Patrick R. Murray
Co-principal Investigator: Judith Johnson
Total direct costs: \$67,300

9/1/00 - 8/31/01
An evaluation of the groundwater and surface water impacts of swine CAFOs in Maryland
Principal Investigator: Ellen K. Silbergeld
Co-investigator: Judith Johnson
CDC
Total direct costs: \$207,229

9/1/00 - 8/31/01
Survey of Antibiotic Resistant Bacteria in Food Animals, Poultry Workers, and Human Referent Groups
PHS/FDA/CVM
Principal Investigator: O. Colin Stine
Co- director: Judith Johnson
Total Direct costs, \$114,000
First year direct costs: \$114,000

10/1/01-12/31/02
Ureidopenicillins and Carbapenems: Understanding their relative importance as risk factors for antibiotic-resistance
Merck & Co., Inc.
Principal Investigator: Anthony Harris, MD
Co-investigator: Judith Johnson
Total direct costs: \$30,000

9/1/01 - 8/31/06	First year direct costs: \$30,000 Prevention of Infection in Indian Neonates NIH Global Network for Women's and Children's Health Research Principal Investigator: Pinaki Panigrahi Co- director: Judith Johnson Total direct costs: \$3,233,856
4/01/03 - 3/31/06	First year direct costs: \$499,079 Molecular Epidemiology of Anitbiotic Resistance After Spinal Cord Injury Department of Veterans Affairs Merit Review Principal Investigator: Mary-Claire Roghmann. Co-investigator: Judith Johnson Total direct costs: \$418,900
10/01/04 - 9/30/07	First year direct costs: \$139,400 Diarrhea in Baltimore: Surveillance and Pathogen Detection Discovering Novel Causes of Foodborne Illness Principal Investigator: Jon Mark Hirshon Co-investigator: Judith A. Johnson Total direct costs \$707,067
7/1/02-6/30/04	First year direct costs: \$235,689 Biohazard detection using metal-enhanced fluorescence NIH R21 AI053658 Principal Investigator: Joseph R. Lakowicz, PhD Co-investigator: Judith A. Johnson, Total direct costs: \$300,000
4/1/05 - 3/30/09 <i>aeruginosa</i>	Epidemiology of Imipenem-resistant <i>Pseudomonas</i> NIH R01 AI060859 Principal Investigator: Anthony Harris. Co-investigator: Judith Johnson Total direct costs: \$850,000
4/1/06 - 3/30/09	First year direct costs: \$250,000 Predicting Antibiotic Resistant Bacterial Carriage at Hospital Admission Department of Veterans Affairs HSR&D Principal Investigator: Eli N. Perencivich. Co-investigator: Judith Johnson Total direct costs: \$704,200
05/01/10 - 04/30/12 spread	First year direct costs: \$244,800 UF 2010 Research Opportunity Seed Fund: Development of a phylogeographic framework to investigate the origin and of cholera pandemics Total direct costs: \$88,000 Co-investigator: Judith Johnson
05/01/10 - 04/30/12	UF 2010 Research Opportunity Seed Fund: Epidemiology and environmental reservoirs of mycobacteria in Florida Total direct costs: \$85,610 Co-investigator: Judith Johnson
03/01/12 - 09/30/12	DOD-GEIS (Ali) Clinical Surveillance for Cholera and Other Enteric Pathogens in Haiti Total direct costs: \$220,000 Role – Co- investigator

Contracts and Small Grants, PI

1998 - 1999	Clinical outcome of infections caused by ESBL producing strains of <i>Klebsiella</i> and <i>E. coli</i> treated with cefepime, in clinically ill surgical patients, subcontract for microbiology ICU Surveillance Study (ISS): Incidence of multiresistance in serial Gram-negative isolates from ICU's - 1998
1999	Merck & Co., Inc. Total costs - \$1,500 (completed)
1999	In vitro evaluation of vancomycin susceptible <i>E. faecalis</i> against imipenem, meropenem, ciprofloxacin, levofloxacin and trovofloxacin - 1998
1999	Merck & Co., Inc. Total costs - \$750 (completed)
1999	Moxifloxacin Regional and National In-vitro Susceptibility of Common Respiratory Tract Pathogens (MSP)
	Bayer, Co/The SuperNova Co. Total costs \$5,000 (completed)
2000	ICU Surveillance Study (ISS): Incidence of multiresistance in serial Gram-negative isolates from ICU's - 1999
2000	Merck & Co., Inc. Total costs - \$1,500 (completed)
2000	Newer Beta-Lactamases Project
10/99 - 6/00	Merck & Co., Inc. Total costs - \$1590 (completed)
	Comparative In Vitro Microbiologic Surveillance Study for Respiratory Tract Infection (1273-BMS-099E)
	Bristol-Myers Squibb/International Health Management Associates, Inc. Total costs \$5,000 (completed)
8/3/99	Molecular typing of enterococcal isolates
1999	Pharmacia & Upjohn Total costs \$500
	Analysis of Imipenem Resistant <i>Pseudomonas aeruginosa</i> Isolates
2000	Merck & Co., Inc. Total costs - \$3,500 (completed)
2000	The ZAPS (Zyvox® Antimicrobial Potency Study)
	The Clinical Pharmacokinetics Laboratory
	Total costs \$2150 (completed)
2000	In vitro evaluation of vancomycin susceptible <i>E. faecalis</i> against imipenem, meropenem, ciprofloxacin, levofloxacin and moxifloxacin - 1999
	Merck & Co., Inc. Total costs - \$1500 (completed)
2001	ICU Surveillance Study (ISS): Incidence of multiresistance in serial Gram-negative isolates from ICU's - 2001
2001	Merck & Co., Inc. Total costs - \$1,500 (completed)
2001	In Vitro Comparison of the Activity of Gatifloxacin, Levofloxacin, Grepafloxacin, and Gemifloxacin against Clinically Important Organisms.
	SmithKline Beecham Pharmaceuticals
	Total costs - \$5000 (completed)
2001	Evaluation of Intra-Site Performance Reproducibility of the Osmetech Microbial Analyser™ in the Detection of Urinary Tract Infection. Protocol #CP-004-C Osmetech plc (completed)
2001	PROTEKT-US Respiratory Survey. clinical microbiology Institute (completed)
2002	ICU Surveillance Study (ISS): Incidence of multiresistance in serial Gram-negative isolates from ICU's - 2002
	Merck & Co., Inc. Total costs - \$1,500 (completed)

Clinical trials supported by VAMHCS Clinical Microbiology and Molecular Diagnostics Laboratory

- 1998 - 1999 Linezolid for the Treatment of Vancomycin-Resistant Enterococcal Infections: A Double-Blind Trial Comparing 600 mg Linezolid Every 12 Hours with 200 mg Linezolid Every 12 Hours M/1260/0054
Pharmacia & Upjohn
- 1998-1999 Phase II Clinical Trial to Evaluate the Safety and Effectiveness of an Enterocolonic Formulation of Bovine Anti-*Clostridium difficile* Toxin A and B Milk Immunoglobulin (DiffGAM™) on Reducing the Severity of *C. difficile* Associated Diarrhea (CDAD)
ImmuCell Corporation #ICC-0302-1988
- 1999 A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0826 Versus Ceftriaxone Sodium in the Treatment of Serious Community-Acquired Pneumonia in Adults. Merck & Co. Inc. #018-00
- 1999 A Phase-II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Compare Two Doses of Ramoplanin and Placebo in the Decontamination of the Gastrointestinal System Colonized by Vancomycin-Resistant Enterococcus.
Pharmaceutical Research Associates, Inc.
- 1999 A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0826 Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults.
Merck & Co. Inc. #014-00
- 1999 A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0826 Versus Piperacillin/Tazobactam in the Treatment of Complicated Skin and Skin Structure Infections in Adults.
Merck & Co. Inc. #016-00
- 1999 - 2000 Open-Label, Comparative, Randomized, Multicenter Phase III Study of Intravenous Treatment of Synercid 7.5 mg/kg q 8 hours plus Aztreonam 2g q 8 hours versus Standard Therapy in the Treatment of 250 Adult Evaluable Hospitalized Patients with Nosocomial Pneumonia due, at least in part, to Gram Positive Cocci.
Rhone-Poulenc Rorer Recherche-Developpement
RP59500V-311
- 2000 A Multicenter, Investigator-blinded, Randomized Study to Compare the Safety and Efficacy of IV Daptomycin with that of Vancomycin or a Semi-Synthetic Penicillin in the Treatment of Complicated Bacterial Skin and Soft Tissue Infections Due to Gram-Positive Bacteria
Cubist Pharmaceuticals, Inc. DAP-SST9801
- 2002 - 2003 An Open-Label, Randomized, Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients
Wyeth-Ayerst Pharmaceuticals Inc. #0910X-100468-US
- 2002 - 2003 Stich Study. A Prospective, Multicenter, Double-Blind with In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem

- 2002 - 2003 Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults. Merck & Co. Inc. #037-01 - ERT516
Side Step Study. A Prospective, Multicenter, Double-Blind with In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.
- 2003 - 2004 Merck & Co. Inc. #034 - ERT502/Protocol 034
A Randomized Double-Blind, Double-Dummy, Phase III, Comparative Study of Cidecin (Daptomycin) and Zyvox (Linezolid) in the Treatment of Hospitalized Adults with Suspected Vancomycin-Resistant Enterococcal Infections
- 2003 - 2004 Cubist Pharmaceuticals, Inc. DAP-VRE-00-07
A Phase III, Randomized Double-Blind, Comparative Study of
- 2003 - 2004 Micafungin (MK463) Versus placebo as Preemptive Antifungal Therapy in Patients in the Intensive Care Unit Fujisawa healthcare Inc #01-0-124 Micafungin
Phase III, Randomized, double-blind, multicenter study to evaluate the safety and efficacy of dalbavancin versus cefazolin in the treatment of uncomplicated skin and soft tissue infections with suspected or confirmed gram-positive bacterial pathogens
- 2003 - 2004 Versicor, Inc. VER001-8
Phase III, Randomized, double-blind, multicenter study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of uncomplicated skin and soft tissue infections with suspected or confirmed gram-positive bacterial pathogens
- 2003 - 2004 Versicor, Inc. VER001-9
A Prospective, Multicenter, Double-Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults. (Stitch Study)
- 2004 Merck & Co. Inc. ERT516 #037-011
A Phase3, Multicenter, Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia.
- 2004 - 2007 Wyeth, Inc. 3074A1-311-WW
A Phase3, Multicenter, Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Tigecycline versus Levofloxacin to Treat Subjects Hospitalized with Community-Acquired Pneumonia.
- 2004 - 2007 Wyeth, Inc. 3074A1-308-WW
A Phase III, , Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Dalbavancin versus Cefazolin in the Treatment of Uncomplicated Skin and Soft Tissue Infections with
- Suspected or Confirmed Gram-Positive Bacterial Pathogens.
- 2004 - 2007 Versicolor, Inc. VER001-8
A Phase III, , Randomized, Double-Blind, Multicenter

	Study to Evaluate the Safety and Efficacy of Dalbavancin versus Linezolid in the Treatment of Complicated Skin and Soft Tissue Infections with Suspected or Confirmed Gram-Positive Bacterial Pathogens. Versicolor, Inc. VER001-9
2004 - 2007	Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections Pharmacia PHA-OXAA-0026
2005 - 2006	A Multicenter, Open-Label Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Imipenem in Ventilator-Associated Pneumonia Peninsula Pharmaceuticals, Inc. DORI-10
2005 - 2006	A Multicenter, Open-Label Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem in Hospital Acquired Pneumonia Peninsula Pharmaceuticals, Inc. DORI-9
2005 - 2006	Micafungin (FK463) versus Placebo in Patients in the Intensive Care Unit Fujisawa Pharmaceuticals, Inc. 01-0-124
2005 - 2007	LEAPS: Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue Infections Proved to be
Due	to Methicillin-Resistant <i>Staphylococcus aureus</i> . Pfizer, Inc. A5951002
2006-2007	A Double-Blind, Randomized, Controlled Trial of Rifamixin Compared to Vancomycin for the Treatment of <i>Clostridium difficile</i> -Associated Diarrhea (CDAD). Salix Pharmaceuticals, Inc. Xifaxan RFCL3001
2006	Theravance, Inc. 0015
2006	Theravance, Inc. 0018
2006-2007	Genzyme Co. GD3-170-301
2006-2007	A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin and skin structure infection. Cerexa P-903-06 and P-903-07.
2006-2007	A phase 3, randomized, double-blind, study of Ceftobiprole medocaril vs linezolid plus ceftazidime in the treatment of nosocomial pneumonia. Advanced Biologics BAP00248.
2006 -2007	Study of the efficacy and safety of moxifloxacin in the treatment of diabetic subjects with infections of the foot Schering-Plough Research Institute
	P05000.

15. Teaching Activities:

2007 - present	Pathology Residents, Clinical Microbiology Rotation - team taught with Dr. Ken Rand
2008 - 2009	IDP program, Grant writing – team taught with Dr. Laurence Morel
2011	GMS 6121 Infectious Diseases - fungal pathogens and parasites lectures

Dissertation or Thesis Committees/Examiner	
Graduates	
1994	Taheri S. Lashkerwala , M.S. Project: Molecular Epidemiology of Group B <i>Streptococci</i> (direct supervision; primary advisor Dr. J. Glenn Morris, Jr.)
1995	Augusto Franco , Ph.D. Universidad Peruana Cayetano Heredia, Lima Project: Rugosity and <i>dnaE</i> in <i>Vibrio cholerae</i> (direct supervision; primary advisor Dr. J. Glenn Morris, Jr.)
1997	Thomas P. Iarocci , M.S., Project: Role of investigational antibiotics and immunotherapy against multiply-resistant enterococci (primary advisor, Dr. Richard Schwalbe)
1998	Tuhui Wang , M.S. Department of Chemistry and Biochemistry, UMBC. Project: Determination of the absolute configuration of sugar residues in the capsular
polysaccharides	
1999	of <i>Vibrio vulnificus</i> . (primary advisor Dr. C. Allen Bush) Marcie L. Baer , Ph.D., Department of Oral and Craniofacial Biological Sciences. Project: Molecular Characterization of the Bacterial Predator, <i>Bdellovibrio</i> (primary advisor Dr. Henry Williams)
1998	Mohammed Afsar Ali , Ph.D., MEES Program Project: Phenotypic and genetic characterization of the rugose variant of <i>Vibrio cholerae</i> (direct supervision; primary advisor Dr. J. Glenn Morris, Jr.)
1999	Srinivas Rao , Ph.D., Department of Pathology Project: Development of a transgenic animal model. (primary advisor Dr. Louis J. DeTolla)
1999	Shamantha Gunawardena , Ph.D., Department of Chemistry and Biochemistry, University of Maryland, Baltimore Campus. Project: Structural Investigatin of pathogenic bacterial capsular polysaccharides by heteronuclear multidimensional nuclear magnetic resonance spectroscopy (primary advisor C. Allen Bush)
2000	Xueling Lu , M.S., Department of Chemistry and Biochemistry, University of Maryland, Baltimore Campus. Project: Preliminary investigation on specific degradation of the capsular polysaccharide of <i>Vibrio cholerae</i> O139 (primary advisor C. Allen Bush)
2000	Andrew Snyder , Masters student MEES Program Project: Diversity and Ecology of <i>Bdellovibrio</i> (primary advisor, Henry Williams)
2001	Cara Fiore , Ph.D. - Toxicology Program Project: Role of <i>wbfH</i> , <i>I</i> , and <i>J</i> Gene Cluster in <i>Vibrio</i>
<i>cholerae</i>	
2001	O139 Capsule Production Ellen (Trigiani) Fernandez , Ph.D., Department of Pathology Project: The Capsular Polysaccharide of <i>Vibrio cholerae</i>
O139	
2001	Bengal: Induction and Modulation of Host-Cell Mediated Immune Responses Sadaf Qayumi , Masters Student - Department of Medical and Research Technology Project: Streptogramin Resistance in

- 2001 *Enterococcus faecium* (direct supervision; co-advisor)
Angela McIntosh, Ph.D., Department of Pathology
Project: Recovery and Characterization of High-Level
Gentamicin Resistant Strains of *Enterococci* from
Commercial Poultry
- 1995 - 2001
Program. **Amy (Carnahan) Horneman**, Ph.D. student, MEES
Project: Molecular characterization of *Aeromonas* sp.
(primary advisor, Dr. J. Glenn Morris, Jr.)
- 1999-2003 **Ruby Singh**, Ph.D. MEES Program
Project: Characterization of biofilms in dental units. Dean's
representative (primary advisor, Henry Williams)
- 2002 - 2004 **Antonina Aydanian**, Ph.D. student, Program in Human
Genetics. (primary advisor Dr. O. Colin Stine)
Project: Recombination in the Bacterium *Vibrio cholerae*
- 2002 - 2004 **John Furuno**, Ph.D. student, Department of Epidemiology
and Preventive Medicine. Deans representative (primary
advisor Dr. Eli Perencevich). Project: Predicting Antibiotic
Resistance Outcomes upon Hospital Admission
- 2000 - 2005 **Rigoberto Sanchez**, Ph.D. student, Department of Pathology
(primary advisor Dr. Louis J. DeTolla). Project:
Transplantation of Genetically Modified Hepatocytes
Containing a Copper-Transporting ATPase, Direct Hepatic
Delivery, and the Potential Treatment of Wilson's Disease
- 2005 **Daniel C. Edelman**, Ph.D. student, Department of Pathology
(primary advisor Dr. Louis J. DeTolla). Project: Human
Herpes Virus 8: Diagnosis and Serologic Investigations of a
Novel Human Pathogen
- 2004 - 2006 **Yuansha Chen**, Ph.D. student, MEES Program (primary
advisor Dr. J. Glenn Morris, Jr.) Project: *V. cholerae*
- 2004 - 2007 **Mohammed H. Raschid**, Ph.D. student, Dhaka University
(primary advisor Dr. Glenn Morris).
Project: Genetics and Physiology of the Rugose Phenotype of
Vibrio cholerae.
- 2004 - 2008 **Cynthia Stine**, Ph.D, Graduate Student MEES
(primary advisor Dr. Andrew Kane) Project: Mycobacterial
infections of fish
- 2008 - 2010 **Katherine Maldonado DVM, MPH**
Masters Student, University of Florida, College of Veterinary
Medicine, Dept. Infectious Diseases & Pathology (primary
advisor: Maureen Long) Project: MRSA in companion
animals
- 2008 - 2010 **Johanna Carolina Sierra**, Graduate Student Biomedical
Sciences University of Texas Medical Branch (primary
advisor: Dr. Ashok Chopra), Project: Characterization effector
protein, AexU, secreted via Type III secretion system in
Aeromonas hydrophila.
- 2008 - 2011 **Stephanie Yarnell**, MD-PhD student, Project: Non-
tuberculous mycobacteria in Florida
- 2009 - 2011 **Congrong Yu**, PhD student, IFAS (primary advisor: Dr.
Rafael Munoz-Carpena). Project: Colloid and Solute
Transport in Surface Runoff

- 2011 - 2012 **Michael Hubbard**, M.S. student IFAS (primary advisor: Dr. Anita Wright) The effects of salinity and salinity upshifts on the in vitro growth and survival of pathogenic *Vibrio* species
- 2010 - 2013 **Navya Mastianaiah** PhD student MAE (primary advisor Dr. Subrata Roy) Project: Development of a DDB atmospheric low temperature plasma sterilization device
- 2011 - 2013 **Rebecca Lazensky**, PhD student Veterinary Medicine (primary advisor: Dr. J. Glenn Morris). Project: Copepods and cholera
- Ongoing**
- 2010 - present **Taj Azarian**, PhD. student, PPHP (primary advisor: Robert Cook). Project: Community transmission of MRSA
- 2012 - present **Meer Taifur Alum**, PhD. student Dhaka University (primary advisor: Dr. Glenn Morris). Enteric Pathogens in Haiti
- 2012- present **Margo Klar**, PhD. student PPHP (primary advisor: Dr. Linda Cottler) recipient of a Gates Global Challenges Explorations grant for role of materials in umbilical scissors on survival of pathogens causing neonatal sepsis
- 2012 – present **Alex Weppelmann** , PhD. student PPHP (primary advisor: Dr. Afsar Ali) Project: Environmental reservoirs of *Vibrio cholerae* in Haiti
- 2013 – present **Raies Mir**, PhD student CLAS Department of Animal Sciences (primary advisor Dr. Kwang Cheol Jeong) Project: ESBL producing Gram-negative bacilli in cattle
- 2013 – present **Aline Barth** PhD student MAE (primary advisor Dr. Hartmut Derendorf) Project: Pharmacodynamics of fluoroquinolones in treatment of TB

Supervision of Other Graduate Students and Fellows

- 1994-1995 **Laurie Comstock-Villa**. Postdoctoral Fellow
Project: Characterization of the genetics of capsule biosynthesis in *V. cholerae* O139 Bengal (direct supervision; primary advisor James B. Kaper, Department of Medicine).
- 1996 **N.K. Brahmadathan**, Research Fellow, JHU
Project: Molecular typing of pneumococci.
(direct supervision; primary advisor, Dr. Mark Steinhoff)
- 1996 **James Allen Krum**, Lockheed-Martin Graduate Fellow.
Project: Development of nonradioactively-labelled probes for antimicrobial resistance genes in *Enterococci*.
- 1998 – 1999 **Kerri-Lynn Sheahan**, Masters Student Department of Pathology. Project: Bacteriophage therapy for vancomycin resistant enterococci
- 2001- 2002 **Damiola Akinmade**, Graduate Student, rotation Department of Pathology
Project: Antibiotic resistance in commensals of poultry
- 2001- 2002 **Jacob Adeyeye**, Postdoctoral Fellow,
Department of Chemistry and Biochemistry, UMCP
Project: Interaction of phage with the capsule of *Vibrio cholerae* O139 (Codirection with Dr. C. Allen Bush.)
- 2002 - 2003 **Lucia Nemoy**, Infectious Diseases Fellow, Department of Epidemiology and Preventive Medicine. (primary advisor

2002 - 2003	Dr. Anthony Harris) Project: Carriage of ESBLs in the intensive care setting Aileen Dualen , ABD Ph.D. student, Department of Epidemiology and Preventive Medicine. (primary advisor Dr. Anthony Harris). Project: Fluoroquinolone resistant <i>Pseudomonas aeruginosa</i> in the intensive care setting or Risk Factors for the acquisition of imipenem-resistant
pseudomonas	
2003 - 2004	<i>aeruginosa</i> among ICU patients. Habibul Bari Mahmud Bakht , Ph.D. student, MEES Program. Withdrew
2004	Zachary Cooper Ph.D. Student, rotation Department of Pathology Project: Antibiotic resistance in enteric flora of spinal cord injury patients.
2004 - 2007	Patricia Anderson , Ph.D. student, rotation Department of Pathology Project: Mutator strains in <i>Vibrio cholerae</i>
2005	Maureen O'Donnel Ph.D. Student, rotation Department of Pathology Project: Antibiotic resistance
1996 - 2007	Scott A. Thornton , Ph.D candidate, Department of Microbiology, UMCP. Project: Acquisition of multiresistant strains of <i>Enterococcus</i> and <i>Staphylococcus</i> in hospitalized and community-based populations (primary advisor, Dr. Sam Joseph)
2002 - 2008	Russel Dorsey , Ph. D. student, Department of Pathology (primary advisor Dr. Niel Constantine) Project: Real-time amplification-boosted detection of biological threat toxins.
2003 - 2007	Damiola Akinmade , Ph.D. student, Department of Pathology (primary advisor Dr. Anne Hamburger) Project: Effects of Epb1 phosphorylation on its subcelular localization and protein-protein interactions.
2004 - 2007	Patricia Anderson , Ph.D. student, Department of Pathology Project: Mutator strains of <i>Vibrio cholerae</i>
2005 - 2007	Soumya Ganguly , Graduate Student MEES (primary advisor Dr. C. Allen Bush)
2010	Chad Dante Neilsen , PhD. student, PHHP (primary advisor: Robert Cook). Project: Phylogeography of MRSA
2012	Stephen Cassle , M.S student laboratory rotation. MRSA in cetaceans.
2012- 2013	Laureen Meroueh PhD student MAE (primary advisor Dr. Subrata Roy) Project: Development of DDB plasma water disinfection system. Did not complete program
Supervision of Other Students	
1993	Kyanni Buynum , Gifted Minority Student Research Program. Project: Detection of Chlamydia and group B <i>Streptococci</i> by PCR.(co-advisor)
1994 -1995	Lubna Nabulsi , Department of Medical and Research Technology, Senior Research Project. Project: Capsules of <i>Vibrio cholerae</i>
1995	Jennifer Kriss , Undergraduate, Delaware Valley, Summer

- project. Project: Relationship of serotype and ribotype in *V. cholerae*
- 1995 **Aatif Hayat**, High School summer student.
Project: Comparison of methods for identification of vibrios
- 1995 **Carol Swanson**. Pathology Senior Project: Vertical transmission of HIV: is breast feeding a serious risk?
- 1995 - 1996 **William Manyi Nsoesie**, Independent Project, Master of Science in Interdisciplinary Science Studies, Johns Hopkins University. Project: Development of probe for *cps* gene from *Vibrio cholerae* strain NRT-36S
- 1996 **Marjorie Paloma**, Undergraduate summer student.
Project: Comparison of commercially available methods for identification of *Vibrio* species.
- 1996-1997 **Luu Pham**, High School student - Woodlawn Magnet Research Mentorship Program. Project: Molecular typing of pneumococci.
- 1997 **Norma Shamoon**, Department of Medical and Research Technology, Senior Research Project.
Project: Imipenem Resistance in *Pseudomonas aeruginosa*
- 1997 **Lisa Nissman**: Department of Medical and Research Technology, Senior Research Project. Project: Testing of a *V. cholerae* O139 capsule conjugate vaccine in rabbits.
- 1997 **Jason Duncan**, Department of Medical and Research Technology, Senior Research Project.
Project: Antibiotic resistance in Gram negative bacteria.
- 1997 **Adnan Syed**, High school student - Woodlawn Magnet Research Mentorship Program. Project: Imipenem Resistance in *Pseudomonas aeruginosa*
- 1998 **Kleanthis Dendrinis**, Medical Student STRTP Traineeship.
Project: does *Aeromonas* cause acute diarrhea in young children. (primary advisor Dr. J. Glenn Morris, Jr.)
- 1998 **Pranav Suthar**, Department of Medical and Research Technology, Senior Research Project.
Project: Immunologic cross-reactivity of *V. cholerae* surface polysaccharides.
- 1998 **Cyra Ranji**, Department of Medical and Research Technology, Senior Research Project.
Project: Antibiotic resistance genes in Enterococci: Streptomycin and gentamycin
- 1998 **Kelli Mitz**, undergraduate research project
Project: Detection of virulence genes in *Aeromonas*
- 1998 **Rebekah Geil**, Hammond High School Gifted and Talented Program, Independent Research Project
Project: Antibiotic resistance genes in Enterococci
- 1999 **CharlesK. Cooper**, Infectious Diseases Fellow
Project: Antibiotic susceptibility testing of extended-spectrum beta-lactamases
- 2001 **Mekdes Biru**
Department of Pathology Summer Intern
Project: Antibiotic resistant bacteria in commercial poultry
- 2001 **Matt Woodford**
Department of Pathology Summer Intern
Project: Antibiotic resistant bacteria in commercial poultry
- 2001 **Staci McGonigal**
Summer Intern

- 2002 Project: Recovery of quinolone-resistant *E. coli* from commercial poultry.
Matt Woodford
Department of Pathology Summer Intern
Project: Surveillance for ESBL and AmpC *E. coli* and *Klebsiella* in a major medical center
- 2002 **Cori Miller**
Department of Pathology Minority Summer Intern
Project: Distribution of ESBL and AmpC resistance genes in *E. coli* and *Klebsiella* in a major medical center
- 2002 **Jessica Kalwa**
Villa Julie College Senior Project. (Intern)
Project: Distribution of ESBL and AmpC resistance genes in *E. coli* and *Klebsiella* in a major medical center
- 2003 **Allison Turner**
Science Fair Project: Interaction between *Escherichia coli* and *Aeromonas* from leech and nonleech sources
- 2003 **Gregory Solares Brown**
Department of Pathology Summer Intern
Project: Genetics of *Vibrio cholerae* O antigens
- 2003 **Tamara Huff**
Department of Pathology Minority Summer Intern
Project: Distribution of gram-negative rods resistant to third generation cephalosporins in an ICU setting
- 2003 **Tiffany Langan**
Villa Julie College Senior Project. (Intern)
Project: Horizontal transfer of ESBL and AmpC resistance genes in the intensive care setting
- 2004 **Rebecca Josowitz**
Roland Park Country School Senior Project (Intern)
Project: Carriage of VRE in hospitalized patients
- 2005 **Katherine Coyle**
Villa Julie College Senior Project. (Intern)
Project: Imipenem resistance in *Pseudomonas aeruginosa* in the intensive care setting
- 2006 **Veronica Edwards**
BCCC Biotechnology Rotation. (Intern)
Project: Imipenem resistant Gram-negative bacilli in the intensive care setting
- 2006, 2007 **Diana Miller**
Villa Julie College Junior & Senior Project. (Intern)
- 2006 - 2007 **Amy Treakle, MD**, Infectious Disease Fellow
Project: Carriage of MRSA and VRE on physicians white coats (Primary mentor Dr A Harris)
- 2006 - 2007 **Kerri Thom, MD**, Infectious Disease Fellow
Project: Increasing Prevalence of Gastrointestinal Colonization
- 2006 - 2007 with Ceftazidime-Resistant Gram-negative Bacteria (Primary mentor Dr A Harris)
Graham Snyder, MD, Infectious Disease Fellow
Project: Contamination rate of gloves and gowns during interaction with patients on contact isolation. (Primary mentor Dr A Harris)
- 2008 – present **Grant Jester**, Undergraduate student, Project: Localization of

- 2009 AmpC resistance genes in clinical gram-negative bacilli
Rory Marsh, Undergraduate student, Project: Paleo-bacteriology and phylogeography of the cholera 7th pandemic
- Lectures Given within University Courses
- 1987 "Medical Mycology" MICB440, Pathogenic Microbiology (150 students)
- 1988 - 1990 "Streptococci" MICB440, Pathogenic Microbiology (150 students)
- 1994 "Epidemiology of group B Streptococcus infections" MEDT 671, Molecular Diagnostics (20 students)
- 1996 "*Vibrio cholerae* O139 Bengal - An Update on the Eighth Pandemic" Seminars in Clinical and Diagnostic Pathology (20 students)
- 1995 - 1997 1 day clinical rotation for MEDT433 - Techniques in Biotechnology (8-12 students)
- 1997 "Molecular Diagnostics of Infectious Diseases" PATH608 Advanced General Pathology. (20 students)
- 2000 Prepared and taught two laboratory exercises - Plasmid Profiles, and Pulsed-field Gel Electrophoresis for MEDT470 - Virology and Molecular Diagnostics (23 students)
- 2001 - Plasmid Profiles, and Pulsed-field Gel Electrophoresis for MEDT470 - Virology and Molecular Diagnostics (20 students)
- 2005 Plague for PATH 789 Special Topics - Bioterrorism (8 students)
- 2006 Plague for PATH 789 Special Topics - Bioterrorism (1 student)
- 2008 - 2012 *Vibrio parahaemolyticus* and friends for Water Biology PHC 6937 (~15 students)
- Laboratory Co-ordinator, UMCP
1983-1990 MICB440, Pathogenic Microbiology (150 students)
- Laboratory Instructor, UMCP
1985 - 1989 Immunology (20 students)
1984 Biotechnology (15 students)
1983 Graduate Virology (15 students)
1982 Pathogenic Microbiology (20 students)
- 16. CLINICAL ACTIVITIES**
- 1998 - 2007 Chief, Microbiology and Molecular Diagnostics, Veterans Affairs Maryland Health Care System
- 1997 - 2003 Consultant, Infection Control Program, Division of Hospital Epidemiology, Department of Medicine, UMAB
- 1993 - 1998 Scientific Director, Molecular Diagnostics Laboratory, Veterans Affairs Maryland Health Care System, Baltimore.
- 2008 - 2009 Member, Resistant Pathogen Taskforce, Shands Health Care
- 17. INVITED PRESENTATIONS**
- 1995 "Death on the Half Shell: *Vibrio vulnificus* Contamination of Seafood" Seminar at Perkin-Elmer, Applied Bioscience

- 1995 Division, Foster City, CA. September 15, 1995.
Vibrio cholerae O139 Bengal: The Sugar-Coated Cholera"
Seminar at FDA, Bethesda, MD, October 12, 1995
- 1996 "Molecular Diagnostics for Infectious Diseases"
at the 3-M teleconference program "Microbiology from
Maryland in March 1996"
- 1996 "Epidemiologia Molecular del *Vibrio cholerae*" Análisis
Epidemiológico del Cólera y su Implicaciones en el Programa
de Prevención y Control en México, Mexico City, Mexico
December 10
- 1997
conjugate *Vibrio cholerae* O139 polysaccharide-tetanus toxoid
vaccine candidate. Massachusetts Biologics Institute,
Boston Massachusetts
- 1998 *Vibrio cholerae* O139 capsular polysaccharide protein
conjugate vaccines. XIXth International Carbohydrate
Symposium, San Diego, California, August 1998
- 1999 "Comparison of quinupristin/dalfopristin-resitant
Enterococcus faecium from clinical and poultry sources".
Antibiotic Use in Animals: Food Safety and Risk Assessment.
A Ceres Forum. Georgetown University, Washington, DC
May 1999.
- 1999 Press Release, 99th Annual Meeting of the American Society
of Microbiology, Chicago, Illinois, May 1999.
"Transfer of Gentamicin Resistance from Commercial Poultry
Strains of Enterococci"
- 1999 "The *Vibrio cholerae* O139 Bengal story: clinical and
molecular basis for emergence of a new pandemic strain"
American Society of Tropical Medicine and Hygiene.
Washington D.C., November 1999
- 2000 "The Biology of Antibiotic Resistant Enterococci in Poultry"
Grand Rounds, The Maryland Campus of Regional Veterinary
Medicine, College Park, MD March 2000
- 2000 "Antibiotic Resistance" Fall Colloquium, Joint Institute of
Food Safety and Nutrition and the University of Maryland
Program in Toxicology, Baltimore, MD, September 7, 2000
- 2003 "ID and treatment of *Vibrio* Infections"
20th Annual Current Topics in Microbiology
The Maryland Society for Clinical Laboratory Science and
The Microbiology Laboratory at Anne Arundel Medical
Center. Annapolis MD February 2003
- 2004 "Updates on antibiotic susceptibility testing"
21st Annual Current Topics in Microbiology
The Maryland Society for Clinical Laboratory Science and
The Microbiology Laboratory at Anne Arundel Medical
Center. Annapolis MD February 2004
- 2005 "Unexplained Causes of Infectious Diarrheal Diseases: or the
Scoop on Poop". 22nd Annual Current Topics in
Microbiology
The Maryland Society for Clinical Laboratory Science and
The Microbiology Laboratory at Anne Arundel Medical
Center. Annapolis MD March 2005
- 2008 "Antibiotic Resistance - Are the Superbugs Winning?"
Florida Community College at Jacksonville, Jacksonville, FL
April 2008

- 2008 “El Niño and Cholera”, Ninety-Forth Annual ASM Southeastern Branch Conference, November, 2008; Jacksonville, FL
- 2009 Discussant for Session 4 “Recent evolutionary change in *Staphylococcus aureus* “, Resources for the Future Extending the Cure and the Emerging Pathogens Institute at the University of Florida co-hosted consultation on the ecology and epidemiology of community-acquired *Methicillin-resistant Staphylococcus aureus* (CA-MRSA), March 5-6, 2009; St. Augustine, Florida
- 2009 “Climate Change and Emerging Infectious Diseases”, IST 29065 Climate change: What does it mean for Florida? Extension Meeting; Plant City, FL; February 18-20, 2009
- 2009 “Climate Change, Pollution & Diseases” Managing Climate Change with Sustainable Initiatives; Fort Myers, FL; December 4, 2009.
- 2009 Expert consultation in support of the project: “IMPLEMENTATION OF LABORATORY SENTINEL SURVEILLANCE FOR NOSOCOMIAL INFECTIONS IN MOROCCO” Royaume du Maroc; Minstere de la Sante; Institut National d’Hygiene; Rabat, Morocco; December 14-20, 2009.
- 2011 “Molecular biology of *V. cholerae*” UF HHMI ICORE Interdisciplinary Center for Ongoing Research/Education Summer Institute: June 12 – 24, 2011
- 2012 “Molecular biology of *V. cholerae*” UF HHMI ICORE Interdisciplinary Center for Ongoing Research/Education Summer Institute: June 10 – 22, 2012
- 2013 “Molecular biology of *V. cholerae*” UF HHMI ICORE Interdisciplinary Center for Ongoing Research/Education Summer Institute: June 2013

18. PUBLICATIONS

Book Chapters

1. Johnson, J.A. Chapter 58. *Vibrio*. In Murray et al eds Topley and Wilson's Microbiology and Microbial Infections 10th Ed. 2006. Edward Arnold Limited; London
2. Abbott, S.L., Janda, J.M., Johnson, J.A., Farmer J.J. III. Chapter 47: Vibrio and Related Organisms. In: Manual of Clinical Microbiology, 9th ed. Murray et al eds. 2007. ASM Press, Washington DC.

Original Journal Articles/Peer Reviewed Journals

1. Johnson, J.A., Panigrahi, P., and Morris, J.G., Jr. Non-01 *Vibrio cholerae* NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. *Infection and Immunity* 1992;60:864-9.
2. Wright, A.C., Guo, Y., Johnson, J.A., Nataro, J.P., and Morris, J.G., Jr. Development and testing of a non-radioactive DNA oligonucleotide probe that is specific for *Vibrio cholerae* cholera toxin. *Journal of Clinical Microbiology* 1992;30:2302-6

3. Johnson, J.A., Morris, J.G., Jr., and Kaper, J.B. Gene encoding zonula occludens toxin (*zot*) does not occur independently from cholera enterotoxin genes (*ctx*) in *Vibrio cholerae*. *Journal of Clinical Microbiology* 1993;31:732-3.
4. Rice, E.W., Johnson, C.H., Clark, R.M., Fox, K.R., Reasoner, D.J., Dunnigan, M.E., Panigrahi, P., Johnson, J.A., and Morris, J.G., Jr. *Vibrio cholerae* O1 can assume a 'rugose' survival form that resists killing by chlorine, yet retains virulence. *International Journal of Environmental Health Research* 1993;3:89-98.
5. Hayat, U., Reddy, G.P., Bush, C.A., Johnson, J.A., Wright, A.C., and Morris, J.G., Jr. Capsular types of *Vibrio vulnificus*: An analysis of strains from clinical and environmental sources. *The Journal of Infectious Diseases* 1993;168:758-62.
6. Johnson, J.A., Salles, C.A., Panigrahi, P., Albert, M.J., Wright, A.C., Johnson, R.J., and Morris, J.G., Jr. *Vibrio cholerae* O139 synonym Bengal is closely related to *Vibrio cholerae* El Tor, but has important differences. *Infection and Immunity* 1994;62:2108-10.
7. Comstock, L.E., Maneval, D., Jr., Panigrahi, P., Joseph, A., Levine, M.M., Kaper, J.B., Morris, J.G., Jr., and Johnson, J.A. The capsule and O antigen in *Vibrio cholerae* O139 Bengal are associated with a genetic region not present in *Vibrio cholerae* O1. *Infection and Immunity* 1995;63:317-323.
8. Preston, LM, Xu, Q., Johnson, J.A., Joseph, A., Maneval, D.R., Jr., Husain, K., Reddy, G.P., Bush, C.A., and Morris, J.G., Jr. Preliminary structure determination of the capsular polysaccharide of *Vibrio cholerae* O139 Bengal AI1837. *Journal of Bacteriology* 1995;177:835-8.
9. Morris, J.G., Jr., Losonsky, G.E., Johnson, J.A., Tacket, C.O., Nataro, J.P., Panigrahi, P., and Levine, M.M. Clinical and immunologic characteristics of *Vibrio cholerae* O139 Bengal infection in North American volunteers. *The Journal of Infectious Disease* 1995;171:903-8.
10. Morris, J.G., Jr., Shay, D.K., Hebden, J.N., McCarter, R.J., Jr., Perdue, B.E., Jarvis, W., Johnson, J.A., Dowling, T.C., Polish, L.B., and Schwalbe, R.S. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center. *Annals of Internal Medicine* 1995;123:250-9.
11. Harrison, L.H., Ali, A., Dweyer, D.M., Libonati, J.P., Reeves, M.W., Elliot, J.A., Billmann, L. Lashkerwala, T, and Johnson, J.A. Relapsing Invasive group B streptococcal infection in adults. *Annals of Internal Medicine* 1995;123:421-7.
12. Comstock, L.E., Johnson, J.A., Michalski J.M., Morris, J.G., Jr., and Kaper, J.B. Cloning and sequence of a region encoding a surface polysaccharide of *Vibrio cholerae* O139 and characterization of the insertion site in the chromosome of *Vibrio cholerae* O1. *Molecular Microbiology* 1996;19:815-26.
13. Sciortino, C.V., Johnson, J.A. and Hamad, A. Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 *Vibrio cholerae*. *Journal of Clinical Microbiology*. 1996;34:897-900.
14. Wright, A., Hill, R.T., Johnson, J.A., Roghman, M.-C., Colwell, R.R., and Morris, J.G., Jr. Distribution of *Vibrio vulnificus* in the Chesapeake Bay. *Applied and Environmental Microbiology* 1996;62:717-24.
15. Franco, A.A., eh, P.-E., Johnson, J.A., Barry E.M., Guerra, H., Mauer, R., and Morris, J.G., Jr. Cloning and characterization of *dnaE*, encoding the catalytic subunit of replicative DNA polymerase III, from *Vibrio cholerae* strain C6706. *Gene* 1996;175:281-283.

16. Morris, J.G., J., Sztein, M.B., Rice, E.W., Nataro, J.P., Losonsky, G.A., Panigrahi, P., Tacket, C.O., and Johnson, J.A. *Vibrio cholerae* O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. *The Journal of Infectious Diseases* 1996;174:1364-8.
17. Schwalbe, R.S., McIntosh, A.C., Qaiyumi, S., Johnson, J.A., Johnson, R.J., Furness, K.M., Holloway, W.J., and Steele-Moore, L. *In vitro* activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. *Antimicrobial Agents and Chemotherapy* 1996;40:2416-9.
18. Roghmann, M.-C., Qaiyumi S., Johnson, J.A., Schwalbe, R., and Morris, J.G., Jr. Recurrent vancomycin-resistant *Enterococcus faecium* bacteriemia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. *Clinical Infectious Diseases* 1997;24:514-5.
19. Losonsky, G.A., Lm, Y., Motamedi, P., Comstock, L.E., Johnson, J.A., Morris, J.G., Jr., Tacket, C.O., Kaper, J.B., , and Levine, M.M. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine *Vibrio cholerae* O139: specificity and relevance to immunity. *Clinical and Diagnostic Laboratory Immunology*. 1997;4:264-9.
20. Bush, C.A., Patel, P., Gunawardena, S., Powell, J., Joseph, A., Johnson, J.A., and Morris, J.G. Classification of *Vibrio vulnificus* strains by the carbohydrate composition of their capsular polysaccharides. *Analytical Biochemistry* 1997;250:186-195
21. Franco, A.A., Fix, A.D., Prada, A., Paredes E., Palomino, J.C., Wright, A.C., Johnson, J.A., McCarter, R., Guerra, H., and Morris, J.G., Jr. Cholera in Lima, Peru, correlates with prior isolation of *Vibrio cholerae* from the environment. *American Journal of Epidemiology* 1997;146:1067-1075.
22. Karaolis, D.K.R., Johnson, J.A., Bailey, C.C., Boedeker, E.C., Kaper, J.B., and Reeves, P.R.. A *Vibrio cholerae* pathogenicity island associated with epidemic and pandemic strains. *Proceedings of the National Academy of Science, USA*. 1998;95:3134-9.
23. Karaolis, D.K.R., Somara, S. Maneval, D.R., Johnson, J.A., and Kaper, J.B. A bacteriophage encoding a pathogenicity island, type IV pilus, and receptor for CTX ϕ in epidemic *Vibrio cholerae*. *Nature* 1999;399:375-379.
24. Sohzamannan, S., Deng YK, Li, M, Sulakvelidze A, Kaper JB, Johnson, J.A., Nair GB and Morris JG, Jr. Cloning and sequencing of the genes downstream of the *wbf* gene cluster of *Vibrio cholerae* serogroup O139 and analysis of the junction genes in other serogroups. *Infection and Immunity* 1999;67:5033-40
25. Gunawardena, S., Fiore, C., Johnson, J.A., and Bush, C.A. The conformation of a rigid tetrasaccharide epitope in the capsular polysaccharide of *Vibrio cholerae* O139. *Biochemistry* 1999;38:12062-71
26. Ali, A. Johnson, J.A., Franco, A.A., Metzger, D.J., Morris, J.G., Jr., Connell, T.D. and Sohzamannan, S. Mutations in the extracellular protein secretion (eps) pathway genes interfere with rugose polysaccharide production and motility of *Vibrio cholerae*. *Infection and Immunity* 2000;68:1967-74.
27. Ali A, Mahmud ZH, Presswala S, Morris JG Jr., Sohzamannan, S, and Johnson JA. Sequence analysis of TnphoA insertion sites in *Vibrio cholerae* mutants defective in rugose polysaccharide production. *Infection and Immunity*2000;68:6857-6864.
28. Stine O.C., Sohzamannan S., Gou Q., Zheng S., Morris J.G., Jr., and Johnson J.A. Phylogeny of *Vibrio cholerae* based on *recA* sequence. *Infection and Immunity*2000;68:7180-7185.
29. Hayes Jr, McIntosh AC, Qaiyumi S, Johnson JA, English LL, Carr LE, Wagner DD, and Joseph SW. High frequency recovery of quinupristin (Synercid) resistant *Enterococcus faecium* isolates from the poultry production environment *Journal of Clinical Microbiology* 2001;39:2298-2299

30. Henning KJ, Hall EL, Dwyer DM, Billmann L, Schuchat A, Johnson JA, Harrison LH, and the Maryland Emerging Infections Program. Invasive group B streptococcal disease in Maryland nursing home residents *The Journal of Infectious Diseases* 2001;183:1138-42.
31. Anriany YA, Weiner RM, Johnson JA, De Rezende CE, and Joseph SW. Salmonella enterica serovar typhimurium DT104 displays a rugose phenotype. *Applied and Environmental Microbiology* 2001;67:4048-4056
32. Harris AD, Perencevich E, Roghmann MC, Morris JG Jr., Kaye K, and Johnson JA. Risk factors for piperacillin tazobactam resistant *Pseudomonas aeruginosa* among hospitalized patients. *Antimicrobial Agents and Chemotherapy* 2002;46:854-8.
33. Harris AD, Smith D, Johnson JA, Bradham DD and Roghmann M C. Risk factors for imipenem resistant *Pseudomonas aeruginosa* among hospitalized patients. *Clinical Infectious Diseases* 2002;34:340-5
34. Smith DL., Harris AD, Johnson JA, Silbergeld EK, Morris JG Jr. Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. *Proceedings of the National Academy of Science, USA* 2002;99: 6434-6439
35. Smith-Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, Johnson JA, Goering RV, and Thomson KS. Plasmid-Mediated, carbapenem-hydrolyzing β -lactamase, KPC-2, in *Klebsiella pneumoniae* isolates. *Journal of Antimicrobial Chemotherapy* 2003;51:711-714.
36. Adeyeye J, Azurmendi HF, Stroop CJM, Sohzammanan S, Williams AL, Adetumbi AM, Johnson JA, Bush CA. Conformation of the hexasaccharide repeating subunit isolated from the *Vibrio cholerae* O139 capsular polysaccharide. *Biochemistry* 2003;42:3979-88
37. Smith DL, Johnson JA, Harris AD, Furuno JP, Perencevich EN, and Morris JG, Jr. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in *Enterococcus faecium*. *The Lancet Infectious Diseases* 2003;3:241-9
38. Donabedian SM, Thal LA, Hershberger E, Perri MB, Chow JW, Bartlett P, Jones R, Joyce K, Rossiter S, Gay K, Johnson J, Mackinson C, Debess E, Madden J, Angulo F, Zervos MJ. Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food. *Journal of Clinical Microbiology*. 2003;41:1109-13.
39. Kelly L, Smith DL, Snary EL, Johnson JA, Harris AD, Wooldridge M, Morris JG Jr. Animal growth promoters: to ban or not to ban?; A risk assessment approach. *International Journal of Antimicrobial Agents*. 2004;24:205-12.
40. Harris, AD, Nemoy, LL, Johnson JA, , Martin-Carnahan A, Smith, DL, Standiford, H, Perencevich, EN. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: Implications for an Active Surveillance Program. *Infection Control and Hospital Epidemiology*. 2004;25:105-108.
41. Roghmann M, Taylor K, Gupta A, Zhan M, Johnson JA, Cross A, Edelman R and Fattom A. Epidemiology of Capsular and Surface Polysaccharide in *Staphylococcus aureus* infections complicated by bacteremia. *Journal of Hospital Infections* 2005;59:27-32.
42. Ali, A., Morris JG, Jr., and Johnson, JA. Sugars inhibit expression of the rugose phenotype of *Vibrio cholerae*. *Journal of Clinical Microbiology* 2005 43: 1426-1429
43. Furuno, J.P., Perencevich, E.N., Johnson, J.A., Wright, M.O., McGregor, J.C., Morris, J.G., Nemoy, L.L., Roghman, M-C, Standiford, H.C., Hebden, J.N., Strauss, S.M., Harris, A.D. Patients at Risk for

- Vancomycin-Resistant *Staphylococcus aureus*: Co-colonization with Vancomycin-Resistant Enterococci and Methicillin-Resistant *Staphylococcus aureus*. *Emerging Infectious Diseases* 2005; 11:1539-44.
44. Nemoy LL, Kotetishvili M, Tigno J, Norris AK, Harris AD, Perencevich EN, Johnson JA, Torpey D, Sulakvelidze S, Morris JG, Jr., Stine OC, Multilocus sequence typing (MLST) vs. pulsed field gel electrophoresis (PFGE) for the characterization of extended spectrum beta lactamase (ESBL) producing *E. coli* isolates. *Journal of Clinical Microbiology* 2005 43: 1776-1781.
 45. Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Finkelstein J, Smith DL, Strauss SM, Perencevich EN. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. *Archives of Internal Medicine*. 2006;166:580-5. 47.
 46. Roghmann MC, Wallin MT, Gorman PH, Johnson JA. Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction. *Archives of Physical Medicine and Rehabilitation*. 2006;87:130
 47. Nataro JP, Mai V, Johnson J, Blackwelder WC, Heimer R, Tirrell S, Edberg SC, Braden CR, Glenn Morris J Jr, Hirshon JM. Diarrheagenic *Escherichia coli* infection in Baltimore, Maryland, and New Haven, Connecticut. *Clinical Infectious Disease*. 2006;43:402-7.
 48. Stine OC, Johnson JA, Norris AK, Perry K, Tigno J, Qaiumi S, Stine MS, Morris JG, Jr., Widespread distribution of tetracycline resistance genes in a confined animal feeding facility. *International Journal of Antimicrobial Agents*. 2007;29:348-352.
 49. Harris, AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemoy LL, Johnson JK. How important is patient-to-patient transmission in extended spectrum β -lactamase *Escherichia coli* acquisition. *American Journal of Infection Control*. 2007;35:97-101.
 50. Chen Y, Johnson JA, Pusch GD, Morris JG, Jr., Stine OC. The genome of non-O1 *Vibrio cholerae* NRT36S demonstrates the presence of pathogenic mechanisms that are distinct from O1 *Vibrio cholerae*. *Infection and Immunity* 2007;75:2645-7
 51. Chen Y, Bystricky P, Adeyeye J, Panigrahi P, Ali A, Johnson JA, Bush CA, Morris JG, Jr. and Stine OC. The capsule biogenesis genes are embedded in the LPS region in a non-O1 *Vibrio cholerae* NRT36S. *BMC Microbiology*. 2007,7:20.
 52. Roghmann MC, Gorman PH, Wallin MT, Kreisel K, Shurland S and Johnson JA. *Staphylococcus aureus* colonization in community-dwelling people with spinal cord dysfunction. *Archives of Physical Medicine and Rehabilitation* 2007;88:979-83
 53. Chen Y, Stine OC, Morris JG, Johnson JA. Genetic variation of capsule/LPS biogenesis in two serogroup O31 *Vibrio cholerae* isolates. *FEMS Microbiology Letters* 2007;273:133-9.
 54. Harris, AD, McGregor JC, Johnson, JA, Strauss, SM, Moore AC, Standiford HC, Hebden JN, Morris JG, Jr. Risk factors for ICU admission colonization with extended spectrum β -lactamase producing bacteria. *Emerging Infectious Diseases* 2007;13:1144-9
 55. Thom KA, Johnson JA, Strauss SM, Furuno JP, Perencevich EN, Harris AD Increasing prevalence of gastrointestinal colonization with ceftazidime-resistant gram-negative bacteria among intensive care unit patients. *Infection Control and Hospital Epidemiology*. 2007;28:1240-6.
 56. Green HP, Johnson JA, Furuno JP, Strauss SM, Perencevich EN, Lautenbach E, Lee D, Harris AD. Impact of freezing on the future utility of archived surveillance culture specimens *Infection Control and Hospital Epidemiology* 2007;28:886-888.

57. Johnson JK, Arduino SM, Stine OC, Johnson JA, Harris AD. Multilocus Sequencing Typing (MLST) Compared to Pulsed-Field Gel Electrophoresis (PFGE) for Molecular Typing of *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*. 2007;45:3707-3712
58. Harris AD, Perencevich, EM, Johnson JK, Paterson DL, Morris JG, Jr., Strauss, SM, Johnson, JA. Patient-to-patient transmission is important in extended spectrum beta-lactamase-producing *Klebsiella pneumoniae* acquisition. *Clinical Infectious Diseases*. 2007;45:1347-50.
59. González Fraga S, Pichel M, Binsztein N, Johnson JA, Morris JG, Jr., Stine OC. Lateral gene transfer of O1 serogroup encoding genes of *Vibrio cholerae*. *FEMS Microbiology Letters*. 2008;286:32-8.
60. Perencevich, EM, McGregor JC, Shardell M, Furuno JP, Harris AD, Morris JG, Jr., Fisman DN, Johnson, JA. Summer Peaks in Gram-Negative Bacterial Infections among Hospitalized Patients Infection Control and Hospital Epidemiology. *Infection Control and Hospital Epidemiology*. 2008;29:1124-31. PMID: 19031546
61. Panigrahi P, Parida S, Pradhan L, Mohapatra SS, Misra PR, Johnson JA, Chaudhry R, Taylor S, Hansen NI, Gewolb IH. Long-term colonization of a *Lactobacillus plantarum* synbiotic preparation in the neonatal gut. *J Pediatric Gastroenterol Nutrition*. 2008;47:45-53.
62. Chopra AK, Graf J, Horneman AJ, Johnson JA. Virulence factor-activity relationships (VFAR) with specific emphasis on *Aeromonas species* (spp.). *J Water Health*. 2009;7 Suppl 1:S29-54.
63. Thom KA, Harris AD, Johnson JA, Furuno JP. Low prevalence of *Acinetobacter baumannii* colonization on hospital admission. *Am J Infect Control*. 2010;38:329-31.
64. Mahmud Z.H., Wright AC, Mandal, S.C., Dai, J., Jones, M.K, Hasan, M., Rashid, M.H., Islam, M.S., Johnson, J. A., Gulig, P.A., Morris, J. G., Ali, A. Genetic Characterization of *Vibrio vulnificus* Strains from Tilapia Aquaculture in Bangladesh. *Applied and Environmental Microbiology* 2010;76:4890-5
65. Chen, Y., Dai, J., Morris, J.G., Johnson, J.A. Genetic analysis of the capsule polysaccharide (K antigen) and exopolysaccharide genes in pandemic *Vibrio parahaemolyticus* O3:K6. *BMC Microbiol*. 2010;10:274
66. Dai, J., Chen, Y., Dean, S., Morris, J.G. Salfinger, M., Johnson, J.A. Multiple Genome Comparison Reveals New Loci for Mycobacterium Species Identification. *Journal of Clinical Microbiology*. 2011;49:144-53.
67. Gray, R.R., Tatem, A.J., Johnson, J.A., Alekseyenko, A, Pybus, O, Suchard, M., Salemi, M. Testing spatiotemporal hypothesis of bacterial evolution using Methicillin-Resistant *Staphylococcus aureus* ST239 genome-wide data within a Bayesian framework. *Molecular Biology and Evolution* 2011;28:1593–1603.
68. Chandel, D.S., Johnson, J.A., Chaudhry, R., Sharma, N., Shinkre, N., Parida, S.N., Misra, P.R., Panigrahi, P. Extended-spectrum β -lactamase producing Gram-negative bacteria causing neonatal sepsis in India in rural and urban settings. *Journal of Medical Microbiology*. 2011;60:500-507.
69. Ali A, Chen Y, Johnson JA, Redden E, Mayette Y, Rashid MH, Stine OC, Morris, JG. Cholera in Haiti: Further Evidence of Very Recent Clonal Origin. *Emerging Infectious Diseases* 2011;17:699-701.
70. Wu BM, Sabarinath SN, R and K, Johnson J, Derendorf H. Suppression of ciprofloxacin-induced resistant *Pseudomonas aeruginosa* in a dynamic kill curve system. *Int J Antimicrob Agents*. 2011;37:519-24
71. Aydanian, A., Tang, L., Morris, J.G., Johnson, J.A.* Stine, O.C.* (*Co-senior authors). Genetic diversity of O-antigen biosynthetic regions in *Vibrio cholerae*. *Applied and Environmental Microbiology*. 2011;77:2247-53.

72. Rand , K.H., Turner, B., Seifert, H., Hansen, C., Johnson, J.A., Zimmer, A. Clinical laboratory detection of AmpC β -lactamase: Does it affect patient outcome? *American Journal of Clinical Pathology* 2011;135:572-6.
73. Kumar S, Lindquist IE, Sundararajan A, Rajanna C, Floyd JT, Smith KP, Andersen JL, He G, Ayers RM, Johnson JA, Werdann JJ, Sandoval AA, Mojica NM, Schilkey FD, Mudge J, Varela MF. Genome Sequence of Non-O1 *Vibrio cholerae* PS15. *Genome Announcements* 2013 Jan;1(1). pii: e00227-12. doi
74. Prospero M, Veras N, Azarian T, Rathore M, Nolan D, Rand K, Cook R, Johnson JA, Morris JG Jr., Salemi M. Molecular Epidemiology of Community-Associated Methicillin-resistant *Staphylococcus aureus* in the genomic era: a Cross-Sectional Study. *Scientific Reports* 2013;3:1902
75. Mastanaiah N,Johnson JA, Roy S. Effect of Dielectric and Liquid on Plasma Sterilization using Dielectric Barrier Discharge Plasma. *PLOS One*. 2013;8:e70840
76. Mastanaiah N, Banerjee P, Johnson JA, Roy S. Examining the Role of Ozone in Surface Plasma Sterilization using Dielectric Barrier Discharge (DBD) Plasma. *Plasma Processes and Polymers* 2013;10:1120–1133
77. Alam MT, Weppelmann TA, Weber CD, Johnson JA, Rashid MH, Birch CS, Brumback BA, Beau de Rochars VEM, J. Glenn Morris, Jr.^{1,5}Ali A. Monitoring Water Sources for Environmental Reservoirs of Toxicogenic *Vibrio cholerae* O1, Haiti. *Emerging Infectious Diseases* 2014;20:356-362.
78. Salemi M, Ali A, Azarian T, Johnson JA, Mohr D, Prospero M, Veras NM Jubair M, Strickland S, Alam MT, Weppelmann TA, Morris JG Jr. Phylodynamics of *Vibrio Cholerae* O1 in Haiti Demonstrates Evidence of Sequential Population Bottlenecks Driven by Positive Selection. *Proceedings of the National Academy of Science, U.S.A.* (submitted)
79. Weppelmann TA, Alam MT, Widmer J, Morrissey D, Rashid MH, Beau de Rochars VM, Morris JG Jr., Ali A, Johnson JA. Evaluation of a Commercial Hydrogen Sulfide Test for Community- Based Microbial Water Safety Assessment in Haiti. 2013 (submitted)
80. Beau De Rochars VEM, Alam MT, Telisma T, Masse R, Chavannes S, Anilis MG, Jean Baptiste C, Guillaume JH, Gelin G, Kirkpatrick EL, Okech B, Weppelmann TA, Rashid M, Karst S, Johnson JA, Ali A, Morris, JG, Jr. Spectrum of Outpatient Illness in a School-Based Cohort in Haiti, with a Focus on Diarrheal Pathogens (submitted)
81. Widmer JM, Morrissey BD, Weppelmann TA, Beau De Rochars VM, Alam MA , Rashid MH, Ali A, Johnson JA, Morris, JG Jr. Assessing Water-Related Infrastructure in Post-Earthquake Haiti: Implications from a Water Point Inventory Project. (submitted)

Other Articles, Letters

1. Rice, E.W., Johnson, C.J., Clark, R.M., Fox, K.R., Reasoner, D.J., Dunningan M.E., Panigrahi, P., Johnson, J.A., and Morris, J.G., Jr. Chlorine and survival of "rugose" *Vibrio cholerae* (letter). *Lancet* 1992;340:740
2. Harrison, L.H., Dwyer, D.M., and Johnson, J.A. Emergence of serotype V group B streptococcal infection among infants and adults (letter). *Journal of Infectious Disease* 1995;171:513
3. Harrison, L.H., Dwyer, D.M., and Johnson, J.A. Response to Relapsing group B streptococcal infection (letter). *Annals of Internal Medicine* 1996;125:350

4. Johnson, J.A., Joseph, A., and Morris, J.G., Jr. Capsular polysaccharide-protein conjugate vaccines against *Vibrio cholerae* O139 Bengal. In (R.M. Faure, ed.) Cholera Vaccines. 2nd Forum in the *Bulletin de l'Institut Pasteur*. 1995;93:285-290. (symposium proceeding)
5. Karaolis, D.K.R., Somara, S. Maneval, D.R., Johnson, J.A., and Kaper, J.B. A bacteriophage encoding a pathogenicity island, type IV pilus, and receptor for CTXØ in epidemic *Vibrio cholerae*. *Nature* 1999;399:375-379.
6. Schwalbe, R.S., McIntosh, A.C., Qaiyumi, S., Johnson, J.A., and Morris, J.G. Jr. Isolation of vancomycin-resistant enterococci from animal feed in the United States (letter) *The Lancet* 1999; 353:722.
7. Morris, J.G. Jr., McIntosh, A.C., and Johnson, J.A. Contamination of animal feed by multiresistant enterococci (Authors' reply) *The Lancet* 1999; 354:163
8. Smith, D.L. & J.A. Johnson: Antibiotic use in animals and the emergence of antibiotic resistance in human commensal microbes and zoonotic pathogens. *OIE International Standards on Antimicrobial Resistance*, 2003 (symposium proceeding)
9. Furuno, J.P., Maguire, J.H., Green, H.P., Johnson, J.A., Heimer, R., Braden, C.R. and Hirshon, J.M. Clinical utility of multiple stool ova and parasite examinations in low prevalence patient populations. *Clinical Infectious Diseases* 2006;43:795-6
10. Mastanaiah N, Saxena U, Johnson J, Roy S. AIAA-2010-1340. Inactivation of Yeast Cells Using Dielectric Barrier Discharge. 48th AIAA Aerospace Sciences Meeting Including the New Horizons Forum and Aerospace Exposition, Orlando, Florida, Jan. 4-7, 2010
11. Mastanaiah N, Wang CC, Johnson J, Roy S. A Computational Diagnostic Tool for Understanding Plasma Sterilization. AIAA conference, Orlando, FL from 4-7 Jan, 2011.

Abstracts

1. Johnson, J.A., Williams, R., and MacQuillan, A. Effects of branched-chain amino acids on the regulation of leucine biosynthesis in *Vibrio parahaemolyticus*. 89th Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1989.
2. Johnson, J.A., Russell, R.G., and Morris, J.G., Jr. Correlation of colonial morphology and pathogenicity of non-O1 *Vibrio cholerae*. Abstr #B207. 91st Annual Meeting of the American Society of Microbiology, Dallas, Texas, May 1991.
3. Johnson, J.A., Panigrahi, P., Russell, R.G., and Morris, J.G., Jr. Role of hemolysin in the pathogenesis of non-serogroup O1 *Vibrio cholerae*. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 1991.
4. Johnson, J.A., Panigrahi, P., and Morris, J.G., Jr. Evaluation of the role of surface polysaccharide and hemolysin in the pathogenesis of non-O1 *Vibrio cholerae*. Poster, 27th Joint Conference of the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Charlottesville, VA, September 1991.
5. Wright, A.C., Guo, Y.-F., Christy, J.B., Johnson, J.A., Hayat, U., Hill, R.T., and Colwell, R.R.. Incidence of *Vibrio vulnificus* in the Chesapeake Bay. Abstr #Q258. 92nd Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.

6. Panigrahi, P., Srinivas, S., Johnson, J.A., and DeTolla, L.J. Modulation of immunity in non-O1 *Vibrio cholerae*. Abstr #B316. 92nd Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.
7. Johnson, J.A., Joseph, A., Panigrahi, P., and Morris, J.G., Jr. Frequency of encapsulated versus unencapsulated strains of non-O1 *Vibrio cholerae* isolated from patients with septicemia or diarrhea, or from environmental sources. Abstr #B277. 92nd Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.
8. Panigrahi, P., Srinivas, S., Johnson, J.A., and Morris, J.G., Jr. Microfilament dependent invasion of Caco-2 cells by Non-O1 *Vibrio cholerae*. Abstr #614, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA. October 1992.
9. Johnson, J.A., Salles, C.A., and Morris, J.G., Jr. Correlation of heat-stable enterotoxin and capsule type of non-O1 *Vibrio cholerae*. Abstr #613, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA. October 1992.
10. Joseph, A., Zulty, J., Russell, R., Johnson, J.A., and Morris, J.G., Jr. AIN-76A produces fatty liver damage in outbred CD-1 mice. Abstr #B246, 93rd Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
11. Lashkerwala, T., Johnson, J.A., Lovchik, J., and Morris, J.G., Jr. Molecular epidemiology of group B streptococci (GBS), and assessment of GBS typing by arbitrary primer-PCR (AP-PCR). Abstr #C260, 93rd Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
12. Johnson, J.A., Hopkins, R.J., Panigrahi, P., and Morris, J.G., Jr. Evidence that the polysaccharide capsule of non-O1 *Vibrio cholerae* NRT-36S mediates attachment to epithelial cells. Abstr #B320, 93rd Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
13. Morris, J.G. Jr., Johnson, J.A., Tacket, C., Losonsky, G., Rice, E.W., Sztein, M., and Nataro, J. Rugose survival forms of *Vibrio cholerae* O1 are virulent for humans. 1993 Annual Meeting of the Infectious Diseases Society of America, October, New Orleans, LA, 1993
14. Johnson, J.A., Albert, M.J., Panigrahi, P., Michalski, J., Ali, M.A., Johnson, R.J., Kaper, J.B., Morris, J.G., Jr. Characterization of non-O1 *Vibrio cholerae* strains from the Bangladesh Epidemic. Abstr # 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, October, New Orleans, LA, 1993
15. Morris, J.G. Jr., Johnson, J.A., E.W. Rice, Tacket, C.O., G.A. Losonsky, M.B. Sztein, and J.P. Nataro. *Vibrio cholerae* O1 can assume a rugose survival form which resists chlorination, but retains virulence for humans. 29th Joint Conference on the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Monterrey, California, December 1993.
16. Johnson, J.A., Albert, M.J., Panigrahi, P., Wright, A.C., Joseph, A., Comstock, L., Trucksis, M., Michalski, J., Johnson, R.J., Kaper, J.B., Morris, J.G., Jr. Non-O1 *Vibrio cholerae* (O139 synom. Bengal) form the India/Bangladesh epidemic are encapsulated. 29th Joint Conference on the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Monterrey, California, December 1993.
17. Johnson, J.A., Comstock, L., Johnson, R.J., Kaper, J.B., Morris, J.G., Jr. *toxR* is common in nontoxigenic *Vibrio cholerae*. Abstr #B274, 94th Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 23-27, 1994.

18. Johnson J.A., Comstock, L., Losonsky, G., Yu, L., Johnson, R.J., Kaper, J.B., Morris, J.G., Jr. Encapsulated *Vibrio cholerae* O139 Bengal are protected from serum killing. Abstr #B273, 94th Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 1994.
19. Panigrahi P., Joseph, A., Johnson, J., Lehrer, R.I., and Morris, J.G., Jr. Effects of defensins on vibrio species. Abstr #B281. 94th Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 1994.
20. Morris, J.G., Tacket, C.O., Johnson, J.A., Nataro, J.P., Losonsky, G.E., Levine, M.M. "Challenge and rechallenge studies with *Vibrio cholerae* O139 Bengal in North American volunteers." 32nd Annual Meeting, Infectious Diseases Society of America. Orlando, Florida, October 7-9, 1994
21. Harrison, L.H., Johnson, J.A., Ali, A., Elliot, J.A., Reeves, M.W., Billman, L., Dwyer, D.M., and the Maryland Bacterial Invasive Disease Surveillance Group. 1994. Relapsing group B streptococcal bacteremia among adults. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, Orlando Florida, 1994
22. Verma, P.R., Allen, N.E., Hobbs, J.N., Jr., Johnson, J.A., Morris, J.G., Jr., and Schwalbe, R.S. Characterization of vancomycin resistance in *Staphylococcus haemolyticus*. Abstr #637. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, Orlando Florida, 1994
23. Comstock, L.E., J.A. Johnson, and J.B. Kaper. Cloning of a region associated with capsule and O antigen expression of *Vibrio cholerae* serogroup O139. Abstr #B28, 95th Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
24. Panigrahi, P., Bamford, P., Joseph, A., G. Losonsky, and Johnson, J. Human immune response to non-O1 *Vibrio cholerae* serotype O139. Abstr #B291, 95th Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
25. Johnson, J., Echeverria, P., Cole, E.M., McDowell, C.I., and Hubner, R.J. Recognition of pathogenic strains of *Vibrio cholerae* with restriction fragments containing ribosomal RNA operon sequences. Abstr #R8, 95th Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
26. Johnson, J.A., Li, Z., Qaiyumi S, Harrison, T, Morris, J.G., Jr., Johnson, R.J., and Schwalbe, R. Distribution of genotypes of vancomycin resistant enterococci (VRE) differs in ill versus colonized patients. Abstr #E37, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, San Francisco CA, 1995
27. Johnson, J.A., Comstock L.E., Michalski, J., Yu, J., Kaper, J.B., and Morris, J.G., Jr. Characterization of the *rfb* region of *Vibrio cholerae* O139 Bengal responsible for expression of O antigen and capsule. Poster, 31st Joint Conference on the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Kiawah Island, South Carolina, December 1995.
28. Panigrahi, P., Johnson, J.A., Losonsky, G., and Morris, J.G., Jr. Immune Response to *Vibrio cholerae* Serotypes O1 and O139. Poster, 31st Joint Conference on the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Kiawah Island, South Carolina, December 1995.
29. Joseph, A., Morris J.G., and Johnson, J.A. Parenteral injection of an O139 *Vibrio cholerae* capsular polysaccharide-tetanus toxoid conjugate is protective against diarrhea in the RITARD model. 96th Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
30. Li, Z., Schwalbe, R.S., Qaiyumi, S., Johnson, R.J., and Johnson, J.A. Detection of vancomycin-resistant enterococci in stool specimens by the polymerase chain reaction. 96th Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.

31. Franco, A.A., Wright, A.C., Prada, A., Paredes E., Palomino, J.C., Johnson, J.A., Guerra, H., and Morris, J.G., Jr. Abstr #Q394. Distribution of toxigenic *Vibrio cholerae* in sewage, river, and irrigation water in Lima Peru. 96th Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
32. Xu, D.-Q., Comstock, L.E., Johnson, J.A., and Morris, J.G., Jr. Molecular cloning and localization of the genes essential for expression of *Vibrio cholerae* O139 polysaccharide in *E. coli*. Abstr #E29, 96th Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
33. Carnahan, A., Ali, A., Kriss, J., Daugherty, S., Hayat, A., Johnson, R.J., and Johnson, J.A. Evaluation of three commercial identification systems with clinically significant *Vibrio* species. Abstr #D108, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, New Orleans, LA, 1996.
34. Ali, A., Franco, A.A., Morris, J.G., Jr., Johnson, R.J., and Johnson, J.A. Abstr #D89. Insertion of *TnphoA* into *espD* prevents expression of the rugose phenotype in *Vibrio cholerae*. 97th Annual Meeting of the American Society of Microbiology, Miami Beach, FL, May 1997.
35. Karaolis, D.K.R., Johnson, J.A., Boedeker, E.C., and Reeves, P.R. A large pathogenicity island in epidemic and pandemic *Vibrio cholerae*. Abstr #B330, 97th Annual Meeting of the American Society of Microbiology, Miami Beach, FL, May 1997.
36. Johnson, J.A., Cole, E.M., Banks, J.G., Carnahan, A., Johnson, R.J., Bruch, D.L., and Corby M.D. Characterization of clinically important *Vibrio* species by the RiboPrinter™ Microbial Characterization System. 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May, 1997.
37. Sozhamannan, S., Johnson, J.A., and Morris, J.G. Jr. Mechanism of horizontal gene transfer - the *Vibrio cholerae* O139 paradigm. Microbial Pathogenesis and Host Defense, Cold Spring Harbor Laboratory Conference. September, Cold Spring Harbor, New York 1997.
38. Washburn, R.G., Charles, C., Johnson, J., and Morris, J.G. Jr. Binding of complement component C3 to serum-resistant *Vibrio vulnificus* and *Vibrio cholerae* is impaired. Abstr # B46, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, Toronto, Canada 1997.
39. Roghmann, M., Brewrink, J., Hebden, J., Daugherty, S., Johnson, J.A., and Morris, J.G., Jr. Rapid increase in isolation of Imipenem-resistant *Pseudomonas aeruginosa*. Abstr # C27, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, Toronto, Canada 1997.
40. Li, M., A. Ali, J.A. Johnson, J.G. Morris and S. Sozhamannan O- antigen switching in *Vibrio cholerae* by homologous recombination Cold Spring Harbor Symposium on Microbial Pathogenesis and Host Response, Sep 22-26, 1997, CSHL, CSH, NY
41. Blake, R.A.L., Bamford, P.D., O'Brien J., Johnson, J.A., and Panigrahi, P. Developmental expression of surfactant protein A in the rat gastrointestinal tract. Eastern Society for Pediatric Research, February, Atlantic City, NJ, 1998.
42. Karaolis, D.K.R., Sozhamannan, S., Johnson, J.A., and Kaper, J.B. Novel non-O1/non-O139 *Vibrio cholerae* containing the VPI and CTXØ. Abstr #B179, 98th Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.
43. Fiore, C.R., Gunawardena, S., Johnson, J.A., Trigiani, E., and Bush, C.A. *Vibrio cholerae* O139 capsular polysaccharide conformation. Abstr #B408, 98th Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.

44. Trigianni, E., Johnson, J.A., and Powell, J. *Vibrio cholerae* O139 Bengal capsular polysaccharide induces cytokine and chemokine production from human peripheral blood mononuclear cells (PBMCs) in vitro. Abstr #E75, 98th Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.
45. Johnson, J.A., and Morris, J.G., Jr. *Vibrio cholerae* O139 capsular polysaccharide protein conjugate vaccines. XIXth International Carbohydrate Symposium, San Diego, California, August 1998
46. Pfaller, MA, Hollis R, Harrington S, Merz WG, Johnson J, Schwalbe R, Morris JG Jr., Berg D, Steele-Moore L, Cole EM, Hochberg AM, Perl T, Roghman M-C, and Fritschel SJ. Geographical Distribution and antibiotic resistance of clinically-significant *Staphylococcus aureus* ribotypes as determined by an electronically-linked network of automated ribotyping systems. Abstr (late-breaker), 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 1998
47. U.S. – Bangladesh Cholera Working Group (Sack RB, Sack DA, Colwell RR, Huq A, Chun J, Zo Y, Grim C, Morris JG, Johnson JA, Ali A, Longini IM, Nizam A, Siddique AK, Islam MS, Yunus MD, Faruque SM, Qadri F, Albert MJ) Epidemiology and ecology of *Vibrio cholerae* in Bangladesh. , 34th Joint Conference on the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Japan, November, 1998.
48. Johnson J.A. Comparison of quinupristin/dalfopristin-resistant *Enterococcus faecium* from clinical and poultry sources. Antibiotic Use in Animals: Food Safety and Risk Assessment. A Ceres Forum. Georgetown University, Washington, DC May 1999.
49. Qaiyumi S., Ranji C.M., Steele-Moore L., Furness K., Mackinson C., Schwalbe R.S., and Johnson J.A. Isolation and characterization of a novel high-level quinupristin/dalfopristin resistant *Enterococcus faecium*. Abstr #A-68., 99th Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
50. McIntosh A.C., Mackinson C.K., Qaiyumi S., Johnson R.J., Morris, J.G., Schwalbe R.S., and Johnson, J.A. Transfer of gentamicin resistance from commercial poultry strains of enterococci. Abstr #A-66, 99th Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
51. Ali A., Johnson J.A., Morris, J.G., Jr., and Sozhamannan, S. The type II secretion system is involved in the expression of rugose polysaccharide by *V. cholerae*. Abstr #B/D-373, 99th Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
52. Ali A., Sozhamannan, S., Daugherty S., Morris, J.G., Jr., and Johnson J.A. Physiologic factors affecting expression of the rugose phenotype of *Vibrio cholerae*. Abstr #N-91, 99th Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
53. McIntosh, A.C., Mackinson, C.K., Qaiyumi, S., Johnson, R.J., Morris, J.G., Schwalbe, R.S., Johnson, J.A. "Transfer of gentamicin resistance from commercial poultry strains of enterococci." 99th General Meeting of the American Society for Microbiology, Chicago, IL, May 30-June 3, 1999.
54. Pfaller, M.A., Hollis, R., Harrington, S., Merz, W.G., Perl, T., Dick, J., Schwalbe, R., Morris, J.G., Johnson, J.A., Roghmann, M.C., Berg, D., Steele-Morre, L., Cole, E.M., Fritschel, A.M., Hochber, A.M. Geographical distribution and antibiotic resistance of clinically significant *Staphylococcus aureus* ribotypes as determined by an electronically linked network of automated ribotyping systems. 99th General Meeting of the American Society for Microbiology, Chicago, IL, May 30-June 3, 1999
55. Snyder A.R., Johnson J.A., and Williams H.N. Genetic diversity shown by ribotyping of Bdellovibrios isolated from nature Abstr #N-30, 99th Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.

56. Siddiqui, A., Hebden J., Qaiyumi S., Johnson J.A., LiPuma J., McMenamin J., Roghmann M., and Mulligan M., An episodic outbreak of *Burkholderia cepacia*. 37th IDSA Annual Meeting, Philadelphia, PA November 1999
57. Johnson J.A., Dick J, Park C, Steele-Moore L, Paolucci. In vitro susceptibility of vancomycin sensitive *E. faecalis* to imipenem, meropenem, ciprofloxacin, levofloxacin and trovafloxacin. 1st International ASM Conference on Enterococci, Banff, Canada, February 2000
58. Qaiyumi, S. McIntosh A, Mackinson C, and Johnson JA. Streptogramin-resistant *Enterococcus faecium* are highly diverse. 1st International ASM Conference on Enterococci, Banff, Canada, February 2000
59. Fiore CR and Johnson JA. Effect of colitose deletion on O139 *V. cholerae* capsule biology. 100th Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
60. Snyder AR, Walker KE, Johnson JA, and Williams HN. Environmental Bdellovibrios exhibit widespread molecular diversity using 16S PCR-RFLP and ribotyping analyses. 100th Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
61. Sozhamannan S, Ali A, Mahmud ZH, Li M, Johnson JA, and Morris JG. O-antigen switching in *Vibrio cholerae* by homologous recombination. 100th Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
62. Johnson JA, Qaiyumi S, English LL, Hayes JH, White DG, Joseph SW, and Wagner DD. Comparison of streptogramin-resistant *Enterococcus faecium* from poultry and humans. 2000 AVMA Annual Convention, Salt Lake City, UT, July 2000
63. Joshi M, Brull R, Sompali N, Qaiyumi S, Johnson JA, Casper P. Clinical outcomes of Cefepime treatment on infections caused by ESBL- and AmpC-producing Enterobacteriaceae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000
64. Mackinson C, Angulo F, Daugherty S, Johnson JA, and the EIP Enterococci Resistance Study Team. Isolation of a vancomycin-resistant *Enterococcus faecium* from commercial poultry. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000
65. Qaiyumi S, McIntosh AC, Mackinson CK, Bohrer V, and Johnson JA. Effect of Virginiamycin on enterococcus colonization in a chicken model. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000
66. Li M, Chen Y, Shimada T, Johnson JA, Morris JG, Stine OC, and Sozhamannan S. Evidence for the emergence of pathogenic non-O1/non-O139 *Vibrio cholerae* by O-antigen switching. Abstr #. 102nd General Meeting American Society of Microbiol. (ASM), Orlando, FL. May 2001
67. McIntosh AC, Qaiyumi S, Johnson JA. 2001 Characterization of Mid and High-level Gentamycin gene transfer between enterococci from human and animal origin. Abstr # 112. 102nd General Meet. American Society of Microbiol. (ASM), Orlando, FL. May 2001
68. Trigiani-Fernandez ER, Sears CL, Trucksis M, Johnson JA, Powell JL, *Vibrio cholerae* O139 Induces IL-8 Secretion From Human Intestinal Epithelial Cells In Vitro Abstr #. 102nd General Meet. American Society of Microbiol. (ASM), Orlando, FL. May 2001
69. Angulo F, Bozigar PS, DeBess E, Donabedian SM, Hershberger E, Johnson J, Johnson S, Jones R, Park M, Perri MB, Rossiter S, Zervos MJ. Quinupristin-dalfopristin resistance in *Enterococcus faecium* isolated from humans, farm animals and retail food. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001

70. Black JA, Hanson ND, Herrera VL, A. Hossain A, Johnson J, Lockhart TJ, Moland ES, Thomson KS. *Klebsiella pneumoniae* (KP) Isolates Producing a Carbapenem Hydrolyzing Enzyme (CHE). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
71. Donabedian SM, Perri MB, Bozigar PS, Hershberger E, Angulo F, Rossiter S, Jones R, DeBess E, Johnson S, Park M, Johnson J, Zervos MJ. Quinupristin-dalfopristin resistance in *Enterococcus faecium* isolated from humans, farm animals and retail food. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
72. Harris AD, Perencevich EN, Roghmann MC, Morris JG, Kaye KS, and Johnson JA. Risk factors for piperacillin-tazobactam-resistant pseudomonas aeruginosa among hospitalized patients. Abstract. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
73. Moland E S, Johnson J, Black JA, Lockhart TJ, Hossain A, Herrera VL, Hanson ND, Thomson KS. *Klebsiella pneumoniae* (KP) Isolates Producing a Carbapenem Hydrolyzing Enzyme (CHE). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
74. Perri MB, Donabedian SM, Angulo FJ, Jones R, DeBess E, Park M, Johnson S, Johnson J, Zervos MJ. Common Molecular Mechanism of Gentamicin Resistance among Enterococci Isolated from Animals, Food and Humans. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
75. Thal, LA, Hershberger E, Jones R, Joyce K, Hill B, Marano N, Rossiter S, Angulo F, Clark N, Tenover F, Gilbert L, Franko E, Steiner C, Johnson J, DeBess E, Madden J, Zervos MJ. Molecular Mechanism of gentamicin resistance among enterococci isolated from humans, food animals, meat and poultry. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001.
76. Hamel KM, Denys GA, Hazen KC, Murray P, Johnson J, Saubolle M. Detection of Vancomycin resistance with the BD Phoenix™ Automated Microbiology System. Abstr #C-118. 103rd General Meeting American Society of Microbiol. (ASM), Salt Lake City, UT. May 2002
77. Nemoy LL, Harris AH, Carnahan AM, Morris JG, Johnson JA, Stine OC: Multiple genetically distinct ESBL isolates within single persons. National Foundation for Infectious Disease, Washington, DC, June 2002.
78. Aydanian A, Morris JG, Johnson JA, Carnahan A, Stine OC: Recombination in *Vibrio cholerae*. Prokaryotic Development, American Society for Microbiology, Quebec, July 2002.
79. Gupte A, Wu Y, Propst M, Fiore C, Roghmann M, Johnson J, Edelman R, Taylor K, Fattom A. Serotyping of *Staphylococcus aureus* (SA) Bacteremia Isolates and their In Vitro Opsonophagocytic Killing Mediated by Antibodies Specific to Type 5 (T5), Type 8 (T8) and 336 Polysaccharides (PS). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.
80. Johnson JA, Murray P, Denys GA, Hazen KC, Saubolle M. Multicenter Evaluation of the BD Phoenix™ System for Detection of Oxacillin Resistant *Staphylococcus aureus*. Abstr #C-117. 103rd General Meeting American Society of Microbiol. (ASM), Salt Lake City, UT. May 2002
81. Nemoy LL, Johnson JA, Stine, OC, Carnahan AM, Morris, JG, Jr., Perencevich EN, Harris AD. Patient-to-Patient Transmission of ESBLs in Tertiary Care ICUs as Detected by Multi Locus Sequence Typing (MLST). Abstr# C2-709. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.

82. Nemoy LL, Johnson JA, Carnahan AM, Harris AD, Morris JG, Jr., Stine, OC. Distribution of TEM and SHV genes in ESBLs. Abstr# C2-1884. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.
83. Aydanian A, Johnson JA, Morris JG, Stine OC: The genetic diversity in *Vibrio cholerae* LPS regions, U.S. Japan Cholera Conference, Washington, D.C. 2003
84. Nemoy LL, Kotetishvili M, Perencevich EN, Harris AD, Tigno JD, Johnson JA, Torpey D, Sulakvelidze D, Morris JG Jr., Stine OC. Multilocus Sequence Typing (MLST) vs. Pulsed Field Gel Electrophoresis (PFGE) for the Characterization of Extended Spectrum Beta Lactamase Producing *E. coli* isolates. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.
85. Stine OC, Perry K, Tigno JD, Johnson JA, Morris JG. Molecular Characterization Of Tetracycline Resistant Bacteria From A Concentrated Animal Feeding Operation (CAFO) 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.
86. Perry K, Tigno JD, Johnson JA, Morris JG, Stine OC: Molecular characterization of tetracycline resistant bacteria from a concentrated animal feeding operation (CAFO). American Biosafety Association, Boston, Mass. October, 2003. **Gross Memorial Prize Winner.**
87. Huff T, Johnson J. Ceftazidime resistant Gram-negative rods in MICU and SICU patients. Abstract. 2003 Annual Biomedical Research Conference for Minority Students. San Diego, CA October 2003
88. Aydanian, A., Johnson, J.A., Morris, J.G., Martin, A., Sozhamamman, S., Stine, O.C. "Comparison of three O-side LPS gene regions of *Vibrio cholerae*." U.S.-Japan Cholera & Other Bacterial Enteric Infections, 38th Joint Panel Meeting, Bethesda, MD, October 8-10, 2003.
89. Aydanian A, Johnson JA, Morris JG, Stine OC: The genetic diversity in *Vibrio cholerae* LPS regions, Genomes Conference, Hixson, England, April 2004.
90. Panigrahi P, Satpathy R, Nanda N, Pradhan L, Mohapatra S, Morris JG Jr, Johnson J, Wright L, Poole K, Parida S and Gewolb I. Reduction of Infant and Neonatal Deaths by Village Level Education and Training and Early Referral to the Hospital in an Indian Community Setting: Society for Pediatric Research Meeting, May 1-5, 2004, San Francisco.
91. Panigrahi P, Satpathy R, Panda P, Pradhan L, Misra P, Jayakar A, Pote M, Shinkre N, Chaudhry R, Gewolb I, Wright L, Poole K, Morris JG Jr., Parida S and Johnson J. Neonatal Sepsis in India: Microbiology of Infection and Role of Bacterial Colonization Society for Pediatric Research Meeting, May 1-5, 2004 in San Francisco.
92. Roghmann M, Cooper Z, Torpey D, Johnson JA. Prevalence of Resistance to Commonly Used Antibiotics among Gram-Negative Bacilli (GNB) in Community Dwelling People with Spinal Cord Injury (SCI). Abstract #C2-1890, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. November 2004.
93. Stine OC, Johnson JA, Keefer-Norris A, Tigno, J, Stine MS, Silbergeld E, Morris, JG. Widespread Distribution of Tetracycline (tet) Resistance Genes in a Concentrated Animal Feeding Operations (CAFO) Abstract #C2-1985, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. November 2004.
94. Nemoy LL, Russo KS, Keefer-Norris A, Tigno J, Johnson JA, Perencevich EN, Morris JG, Stine OC, Harris AD. Multilocus Sequence Typing (MLST) versus Pulsed Field Gel Electrophoresis (PFGE) for the Characterization of Extended Spectrum Beta Lactamase (ESBL) Producing *Klebsiella* Isolates. Abstract #C2-1336, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. November 2004.

95. Black JA, Moland ES, Hossain A, Johnson JA, Campbell M, Lockhart TJ, Olson LB, Thomson KS, Hanson ND. *Klebsiella* Isolates that Co-Produce ESBL and Inducible DHA-Like Plasmid-Mediated AmpC β -Lactamases from Baltimore, MD and Tampa, FL. Abstract #C2-1338, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. November 2004.
96. Nemoy LL, Tigno J, Keefer-Norris A, Perencevich EN, Johnson JA, Morris JG, Stine OC, Harris AD: Occurrence of multiple species of ESBL in a single patient. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill. November 2004.
97. Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Finkelstein J, Smith DL, Strauss SM, and Perencevich EN. Identifying Patients at High Risk for Colonization by Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococci upon Hospital Admission: Use of a Clinical Prediction Rule. 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April, 2005. Los Angeles, CA. (Oral Presentation)
98. Khoie T, Shurland S, Stine OC, Johnson JA, Jerrard D, Flanagan J and Roghmann M. Methicillin-Resistant *Staphylococcus aureus* (MRSA) * An Emerging Pathogen in the Community. At the 45th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA September 21, 2005
99. McGregor JC, Furuno JP, Perencevich EN, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Strauss SM, Harris AD. Evaluation of Comorbidity Risk-adjustment Measures for Use in Studies of Colonization by Methicillin-resistant *Staphylococcus aureus* and Vancomycin-resistant Enterococci Upon Hospital Admission. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. December 2005, Washington DC.
100. Panigrahi P, Mohapatra SS, Satpathy RN, Pradhan L, Misra PR, Chaudhry R, Morris JG, Johnson JA, Gewolb IH, Hansen N, Wright L, and Parida SN. Causes and timing of sepsis and neonatal mortality in the Indian community setting
101. Gorman P, Roghmann M, Wallin M, Johnson J. Prevalence of resistance to fluoroquinolones in gram-negative bacilli colonizing community dwelling people with spinal cord dysfunction
102. Chen Y, Bystricky P, Adeyeye J, Panigrahi P, Ali A, Johnson JA, Bush, CA, Morris JG, Stine OC: The capsule region biogenesis genes are embedded in the LPS region in non-O1 *Vibrio cholerae* NRT36S. FASEB, Tucson, Arizona, 2006.
103. Arduino SM, Harris AD, Tang L, Johnson JA, Stine OC. Molecular mechanisms causing imipenem resistance among *P. aeruginosa* isolates from intensive care units (ICU) patients. Annual Conference on Antimicrobial Resistance. June 26-28. 2006. Bethesda, Maryland. abstract S 7.
104. Nemoy LL, Shurland S, Harris AD, Keefer-Norris A, Langan T, Stine OC, Johnson JA. Are ESBL producing *E. coli* and *Klebsiella* from active surveillance cultures clonal? 46th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco September 2006.
105. Perencevich EN, McGregor JC, Furuno JP, Harris AD, Johnson JA. Seasonal Variation in Three Nosocomial Pathogens: *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Staphylococcus aureus*. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2006, San Francisco, CA.
106. Arduino SM, Stine OC, Tang L, Poole K, Harris AD, Johnson JA. Mechanisms Contributing to Aminoglycoside Resistance among *P. aeruginosa* from ICU Patients. 46th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco September 2006.

107. Harris, A.D., Johnson, J.A., Strauss, S.M., Moore, A.C., Standiford, H.C., Hebden, J.N., Morris, J.G. "Risk factors for colonization with extended spectrum beta-lactamase (ESBL) producing *E. coli* upon ICU admission." 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
108. Ali, A, Anderson, P. E., M. H. Rashid, Y. Chen, O. C. Stine, J. A. Johnson, J. B. Kaper, and J. G. Morris, Jr. 2005. Differential gene Expression profile of *Vibrio cholerae* persisting in a nutrient-poor lake water microcosm and growing in a nutrient-rich medium. 40th U.S.-Japan cholera and other bacterial enteric infections joint panel meeting held in Boston, MA. December, 2006
109. Harris AD, Green HP, Johnson JA, Strauss SM, Perencevich EN, Launtenbach E, Lee D, Furuno JP. Impact of Freezing on Future Utility of Archived Surveillance Cultures. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
110. Treacle A, Thom KA, Furuno JP, , Straus SM, Johnson JA, Harris AD, Perencevich EN. Methicillin-resistant *Staphylococcus aureus* (MRSA) and White Coats of Healthcare Workers. Abstract #391 17th Annual Scientific meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
111. Thom KA, Johnson JA, Straus SM, Furuno JP, Perencevich EN, Harris AD. Increasing Prevalence of Gastrointestinal Colonization with Ceftazidime-resistant Gram-negative Bacteria among Intensive Care Patients. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD
112. Chaudhry R, Sharma N, Chandel D, Misra P, Shinkre N, Johnson J, Panigrahi P. Multi-Clonal Spread of ESBL-Producing Gram-Negative Bacterial-Strains Causing Neonatal Sepsis in India: Implication for Future Outbreaks. 107th General Meeting American Society of Microbiol May 21 - 26, 2007
113. González Fraga S, Pichel M, Binsztein N, Johnson JA, Morris JG, Stine OC. Lateral transfer of serotype encoding genes in O1 *Vibrio cholerae*. 107th General Meeting American Society of Microbiol May 21 - 26, 2007
114. Snyder GM, Perencevich EN, Furuno JP, Thom KA, Roghmann M, Netzer G, Johnson JA, Strauss SM, Harris AD. Acquisition of Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant *Enterococcus* by Healthcare Workers on Infection Control Protective Clothing. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2007, Chicago, IL.
115. Furuno JP, Johnson JA, McDermott PF, Tang L, Warren MS, Strauss SM, Perencevich EN, Morris JG Jr., Blythe D, Lee D, Stine OC. Genetic Relatedness of Enterococci from Humans and Retail Meat and Poultry. 47th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, September 2007
116. Furuno JP, Hebden JN, Standiford HC, Johnson JA, Perencevich EN, Roghmann M, Harris AD. Prevalence of Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Antibiotic-Resistant *Acinetobacter baumannii* at a Long-Term Acute-Care (LTAC) Facility. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. (ICAAC), Chicago, September 2007
117. Chen, Yuansha, Antonina Aydanian, Judith A. Johnson, J. Glenn Morris, Jr., O. Colin Stine. Comparative genomic analysis showed different degree of conservation in different *Vibrio* species. *Vibrio* 2007. November 2007. Paris, France
118. De-Qi Xu, Dennis Kopecko, Judith Johnson. *Vibrio cholerae* O139 O-Antigen Gene Locus Requires Adjacent Group 4 Capsule Secretion Genes for Biosynthesis of Capsule, but not LPS. 108th General Meeting American Society of Microbiology, Washington DC, June 2007

119. Yu, C, Gao, B, Munoz-Carpena, R, Johnson, J.A. 2008. Surface Transport of Colloidal Particles through Dense Vegetation. *AGU 2008 Joint Assembly*. May 27–30, 2008. Fort Lauderdale, FL
120. Dinesh S. Chandel, Rama Chaudhry, Judith A. Johnson, Ira H. Gewolb, Pinaki Panigrahi. Bacterial translocation from the gut: a major cause of sepsis in the newborn Society for Pediatric Research Meeting, Baltimore, MD, May 2-5, 2009
121. Thom, K.A., Miller, D., Harris, A.D., Perencevich, E.N., Johnson, J.A., Hsiao, W., Furuno, J.P. Low Prevalence of *Acinetobacter baumannii* colonization upon Hospital Admission. Annual Scientific meeting of the Society for Healthcare Epidemiology of America. San Diego, CA, April 2009
122. Rand K.H., Bradley Turner, B., Hilary Seifert, H., Christine Hansen, C., Johnson, J. Clinical Laboratory Detection of AmpC: Does it affect patient outcome? Infectious Disease Society of America 47th Annual Meeting, Philadelphia, PA, October 29-November 1, 2009
123. Mahmud ZH, Wright AC, Jones MK, Islam MS, Dai J, Johnson JA, Morris JG, Ali A. Genetic analyses of *Vibrio vulnificus* strains isolated from tilapia fish in Bangladesh. 44th Annual Joint Panel Meeting, U.S.-Japan Cooperative Medical Science Program - Cholera and Other Bacterial Enteric Infections. San Diego, CA, 2009.
124. Chen, Y., Dai, J., Morris, J.G., Johnson, J.A. Molecular analysis of surface polysaccharide genes in pandemic *Vibrio parahaemolyticus* O3:K6. 44th Annual Joint Panel Meeting, U.S.-Japan Cooperative Medical Science Program - Cholera and Other Bacterial Enteric Infections. San Diego, CA, 2009.
125. Marco Salemi, Andrew Tatem, Rebecca Gray, Yuansha Chen, and Judith A. Johnson .Phylogeography of Cholera; Seventh Pandemic Origin and Spread. *Vibrios in the Environment 2010*. Biloxi, MS November 2010
126. Paul A. Gulig, Nima Rezaie, Rupam Sharma, Zahid H. Mahmud, Anita C. Wright, Melissa Jones, Judith A. Johnson, J. Glenn Morris, and Afsar Ali. Emergence of Pathogenic Strains of *Vibrio vulnificus* Isolated from Tilapia in Bangladesh. *Vibrios in the Environment 2010*. Biloxi, MS November 2010
127. Stephanie C. Yarnell, James F.X. Wellehan, Yang Qui, Jason Blackburn, J. Glenn Morris, Jr., Michael Lauzardo, David Ashkin, Judith A. Johnson, and Andrew S Kane. 2010. Environmental Mycobacteria in Florida, USA. 6th International Symposium on Aquatic Animal Health, Tampa FL.
128. Marco Salemi, Andrew Tatem, Rebecca R. Gray, Yuansha Chen, and Judith A. Johnson. Phylogeography of Cholera; Seventh Pandemic Origin and Spread. NIH/NIAID Conference: Bacterial Waterborne and Emerging Infectious Diseases: Collaborative Research Opportunities in North Africa and the Middle East, Nicosia, Cyprus, February 2011
129. Mohammad Jubair, Judith A. Johnson, Andrew A. Kane, J. Glenn Morris, Jr., and Afsar Ali. Isolation and identification of *V. cholerae* non-O1 strains from the aquatic reservoirs in Haiti. 97th Annual Meeting, Southeastern Branch of American Society of Microbiology. Gainesville, FL October 20 - 22, 2011
130. S. C. Yarnell., J. X. F. Wellehan, J. A. Johnson, and A. S. Kane. Non-tuberculous Mycobacteria in Florida. 97th Annual Meeting, Southeastern Branch of American Society of Microbiology. Gainesville, FL October 20 - 22, 2011
131. Amanda Rice, Judith A. Johnson, Gregory C. Gray Improved Isolation of Pathogenic Amoeba from Environmental Samples. EPI Research Day
132. Nizar Maraqa, Sarah Wheeler, Christine Bailey, Diane Halstead, , Joan Abid, Carmen Smotherman, Judith A. Johnson, Mobeen Rathore, Molecular Types of Methicillin-Resistant *S. aureus* (MRSA) Within a

Neonatal Intensive Care Unit (NICU): Evolution Over a 7-Year Period. Pediatric Academic Societies Annual Meeting, May 4-7, in Washington, DC.